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ABSTRACT 
 
Development of an Interleukin 2 Receptor Targeted Gene Therapy Vehicle.         
(May 2005) 
Wanida Wattanakaroon, 
B.S., Khon Khan University, Khon Khan, Thailand; 
M.S., Montana State University, Bozeman, Montana 
Co-Chairs of Advisory Committee:  Dr. Theresa Good 
                                                              Dr. Dragomir Bukur 
 
The effectiveness of most chemotherapeutic regimens is limited by the toxicity of 
the therapy to normal healthy cells.  Therapies to selectively modulate abnormal T cells 
bearing the interleukin 2 receptor (IL-2R) have been developed to treat diseases 
associated with aberrant immune response.  This study describes the development and 
optimization of a targeted gene or oligonucleotide therapy vehicle to IL-2R bearing T 
cells for selective elimination of these cells.  In this work, a monoclonal antibody to the 
IL-2R was used to target the oligonucleotide delivery vehicle which consisted of a 
polyamidoamine dendrimer.  Optimization of the delivery vehicle involves 
understanding the factors that govern its association with oligonucleotide, the pathway 
of IL-2R endocytic trafficking, and the stability of the oligonucleotide in the biological 
milieu.  Oligonucleotide stability in a cellular environment was examined intra- and 
extracellularly.  Results showed that the rate of intracellular degradation of 
oligonucleotides was much greater than extracellular degradation.  Binding of 
oligonucleotides to dendrimers was demonstrated as a function of dendrimer generation.  
The total binding capacities for dendrimers differed depending upon dendrimer size and 
surface group, whereas equilibrium binding affinity was comparable for all dendrimers 
tested.  Binding of oligonucleotide delivery vehicle to the cell surface and subsequent 
internalization was inversely related to dendrimer size, and in all cases, significantly less 
than binding and internalization of the natural ligand for the IL-2R.  Based on 
experimental results, a kinetic model of the delivery vehicle was derived which included 
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the dependence of binding and internalization on dendrimer size and surface charge and 
intracellular degradation of oligonucleotide.  Based on model predictions, we show that 
larger dendrimers carry more oligonucleotide than the smaller dendrimer vehicles, and 
delivery is more effective with larger vehicles.  This work establishes our ability to 
predict the effects of different delivery vehicle properties on oligonucleotide delivery 
and aids in the development of design criteria for new vehicles for delivery of antisense, 
siRNA, or genes to IL-2R bearing cells. 
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CHAPTER I  
INTRODUCTION 
 
Molecular level interventions are being developed in the field of medicine to 
facilitate advanced health care treatments.  Immunomodulatory therapy, or the deliberate 
modification of the normal immune mechanism, holds great promise as a potential tool 
in the treatment of T cell cancers, autoimmune disease, and organ transplantation.  
Cancers of the T cells such as leukemia and lymphoma affect 100,000 people annually 
(The Leukemia & Lymphoma Society, 2004).  Furthermore, it is estimated that 
approximately 70.4 million patients in the United States suffer from autoimmune related 
disease (Arthritis Foundation, 2002; National Multiple Sclerosis Society, 2003-2004).  
Current nonspecific therapies involving the use of immunosuppressive drugs for 
autoimmune diseases have significant side effects.  The immune response associated 
with transplanted tissue antigens limits the success of organ transplantation in routine 
medical treatment.  Therapies to specifically modulate T cell activity can be developed 
to treat a variety of cancers and autoimmune diseases and prolong graft survival. 
In this project, we set out to develop the engineering or rational design of agents 
which deliver oligonucleotides to specific T cells to selectively and effectively modulate 
immune response (in this case to selectively kill one class of T cell).  The plan of 
experimentation and modeling that follows describes the development and engineering 
of such agents.  Achievement of these aims could be used to aid in the new avenues to 
treat diseases associated with aberrant immune response.                                                   
 In chapter II, general background information on the immune system and current 
research regarding receptor targeted treatment are reviewed.  This includes the 
introduction of the immune system, role of T cells and its cytokine receptors in health, 
the role of the lymphokine interleukin 2 (IL-2) and its receptor (IL-2R) in diseases, and 
novel perspectives for their treatment.  For successful development of a more effective 
gene delivery agent, a minimal requirement typically involves an understanding of its 
                                                 
  This dissertation follows the style of Biotechnology and Bioengineering.  
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association with gene (i.e. binding affinity), uptake and transport (i.e. binding to a cell-
specific receptor, internalization, subcellular trafficking, organelle escape, and nuclear 
translocation) into cells, and stability in the biological milieu.  A number of components 
as followed are thus considered in designing and/or modulating a systemic in vitro gene 
delivery vehicle.  In chapter III, the feasibility of using antisense oligonucleotide gene 
therapy as an anti-cancer treatment is assessed.  We test the functional efficacies of 
selected oligonucleotides based on targeting with monoclonal antibody against the IL-2R 
expressed on leukemic cells.  In addition, a high performance liquid chromatography 
(HPLC) technique is employed to explore the rate of degradation of oligonucleotides by 
serum and cytoplasmic nucleases.  The ability of the delivery vehicle to protect the 
oligonucleotide against nuclease degradation is carefully examined.  In chapters IV and 
V, we perform a kinetic analysis of the binding affinity and cellular uptake of the vehicle 
for oligonucleotide delivery.  These data can provide new insights on the 
interrelationship between vehicle properties (size and charge) and efficacy of steps in the 
mechanism underlying gene delivery. 
Having considered various design components, in chapter VI, we propose a 
mathematical model to yield insights into parameters for receptor-mediated gene 
delivery and/or potential therapeutic strategies to treat diseases.  Mathematical models 
provide a means by which different parameters can be altered and can be potentially 
applied to predict experimental data.  Finally, in chapter VII, conclusions from this work 
are drawn and outlines of possible future directions are presented. 
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CHAPTER II 
IMMUNE SYSTEM IN HEALTH AND DISEASE, IL-2/IL-2 
RECEPTOR T CELL SYSTEM, IMMUNOTHERAPY, AND 
ANTISENSE THERAPY AND OLIGONUCLEOTIDE DELIVERY 
 
IMMUNE SYSTEM IN HEALTH AND DISEASE 
 The immune system is a complex network of cells that work coordinately to 
destroy any invader that compromises the health of the host.  Dsyfunction or deficiency 
of components of this complex network can lead to a variety of clinical diseases.  The 
immune response begins when the foreign antigens invade and trigger a series of events 
including T lymphocyte recognition, activation, and antigenic elimination.  Following 
recognition and activation, antigen receptors on the T helper (TH) cell surface bind to 
processed antigens positioned in the groove of major histocompatibility complex (MHC) 
class II molecules present on the surface of antigen-presenting cells (APC), leading to 
the release of IL-2 and interferon γ (IFN-γ).  During the interaction between the TH cell 
and the APC, interleukin 1 (IL-1) is released by the APC to promote IL-2 and IFN-γ 
secretion.  Secreted IL-2 then feeds back to stimulate the expression of IL-2R on the 
surface of TH cells as well as the production of various cytokines.  The binding of 
secreted IL-2 to receptor-positive T cells induces clonal T cell proliferation.  Activated 
TH cells subsequently trigger the activation of T cytotoxic (TC) cells to mediate cellular 
cytotoxicity and proliferation and differentiation of B cells that mediate the antibody-
mediated response (Goldsby et al., 2000; Shames and Kishiyama, 2000).  Figure 2.1 
shows the activation of TH cells and induction of the immune system (Goldsby et al., 
2000).  The cascade of reactions decribed lead the immune response attributes of 
specificity and memory. 
 The proper function of all components of the immune system is essential for a 
healthy immune response.  A number of disease states occur as a result of the 
malfunction or imbalance of one or more immune system components. 
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Figure 2.1.  Activation of TH cells and induction of the immune system. 
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Organ Transplantation 
 Transplantation is the act of transferring cells, tissues, or organs from one site to 
another.  T cells from the transplanted organ attack the transplant recipient, resulting in 
graft versus host diseases (GVHD).  Conversely, T cells from the host can attack the new 
organ, resulting in graft rejection. 
 Graft rejection is mainly caused by a T cell-mediated immune response to 
alloantigens expressed on cells of the foreign graft.  Graft versus host disease is 
somewhat analogous, except that activated T cells from the graft trigger an immune 
response against antigens on the host cells.  Once activated, CD4+ T cells secrete 
cytokines and induce a number of responses from other effector cells.  Many cytokines 
direct alloresponsive T cells to develop an allospecific immune response, leading 
ultimately to either transplant tolerance or rejection.  Proinflammatory cytokines such as 
interleukin 12 (IL-12) and interleukin 15 (IL-15) appear to promote graft rejection 
through directing TH cell differentiation or promoting expansion, survival, and memory 
development, respectively.  On the other hand, immunosuppressive cytokines such as 
interleukin 10 (IL-10) and transforming growth factor β (TGF-β) may induce host 
tolerance through mediating regulatory T cell homeostasis and function (reviewed in 
Walsh et al., 2004).  Soulillou (1999) has shown that anti-IL-2R antibodies against the 
IL-2 high affinity receptor in allorecognition efficiently decreased transplantation 
rejection.  In addition, other growth factors such as interleukin 4 (IL-4), interleukin 7 
(IL-7), and IL-15 may be involved in this phenomenon.  Currently, immunosuppressive 
therapy is used during tissue transplantation.  During tissue transplantation, drugs are 
administered which block the formation of cytokines or their receptors which would aid 
in the mounting of an immune response against the foreign tissue.  Clinically, mitotic 
inhibitors, corticosteroids, cyclosporin A, tacrolimus, FK506, rapamycin, and x-
irradiation have been given to transplant recipients with harmful side effects (Goldsby et 
al., 2000; reviewed in Walsh et al., 2004). 
 During transplantation, the immune system is nonspecifically suppressed.  
Prolonged use of immunosuppressive drugs is associated with high incidences of 
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infection and cancers.  The development of an immunomodulatory strategy that 
specifically suppresses immune response to the donated tissue could significantly 
improve the likelihood of success and function of the donated organ without 
complications associated with the nonspecific immunosuppressive therapies. 
 
Autoimmune Diseases 
 Autoimmune disease, a group of disorders that involve tissue injury or 
pathology, is caused by the activation of autoreactive T cells and/or B cells to self-
antigens, or autoantigens (reviewed in Davidson and Diamond, 2001; Lernmark, 2001; 
Christen and von Herrath, 2004).  This activation can cause cytolysis and tissue 
destruction in the host organism.   
An autoimmune disease is initiated by response to a single antigen.  Later in the 
disease, the evolution of the response causing autoreactivity, referred to as epitope 
spreading, may involve a change in different effector cells and inflammatory mediators 
as the disease progresses (reviewed in Davidson and Diamond, 2001).  Furthermore, an 
increase in susceptibility to autoimmunity is controlled by the genes of the individual 
and the environment (reviewed in Marrack et al., 2001).  Christen and von Herrath 
(2004) reported that autoimmune initiation includes the genetic predisposition, naïve 
lymphocytes that react with autoantigens, and a precipitating event that leads to cell 
activation.  Because autoantigens have been recognized by the autoantibodies associated 
with autoimmune disorders, detection of autoantibodies might help in the development 
of clinical approaches to predict disease (Lernmark, 2001). 
Approaches to the treatment of autoimmune diseases are analogous to treatment 
of GVHD or transplant rejection.  Treatments range from nonspecific 
immunosuppressive regimens to more specific molocular therapies.  Activated T cells, 
expressing the high affinity IL-2R and some co-stimulatory signaling molecules on the 
surface, have been used as targets for treating autoimmune disease (Kremer et al., 2003; 
Swiatecka-Urban, 2003; Nickoloff and Nestle, 2004).  Several studies have shown that 
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selective removal of all CD4+ cells improves symptoms associated with experimental 
autoimmune diseases (Onodera et al., 2003; Nakane et al., 2003; Griffiths, 2004). 
 
Examples of Known Organ-Specific and Systemic Autoimmune Diseases 
 Systemic Lupus Erythematosus.  Systemic lupus erythematosus (SLE), referred 
to as lupus, is a systemic autoimmune rheumatic disease that produces multiple 
autoantibodies (i.e. antinuclear and anti-DNA antibodies) to various tissue antigens 
expressed throughout the host, leading to variable symptoms dependent on the affected 
individual (Goldsby et al., 2000).  Pathologically, the autoantibodies bind to extracellular 
molecules in the target organs and activate the inflammatory effector functions at that 
site, resulting in tissue damage.  Then, the development and propagation of SLE are 
further caused by impairment of normal tissue clearance of those damaged or apoptotic 
cells in tissues (Greidinger and Rosen, 2000). 
 Multiple Sclerosis.  Multiple sclerosis (MS) is a primary demyelinating disease 
of the central nervous system of unknown etiology.  Approximately 400,000 Americans 
acknowledge having MS, and the average person has a one in 1,000 chance of 
developing the disease (National Multiple Sclerosis Society, 2003-2004).  It is generally 
believed that autoreactive T cells contribute significantly to the demyelinating process.  
There are also some suggestions of the cause of MS in certain virus infection (Goldsby 
et al., 2000).   
A variety of immunosuppressive therapies have been tested to date with varying 
degrees of success.  There is a hope that specific elimination of activated T cells would 
serve as a potential improvement in the treatment of MS. 
 Rheumatoid Arthritis.  Rheumatoid arthritis (RA) is a common autoimmune 
disorder that produces a group of autoantibodies called rheumatoid factors.  This disease 
is characterized by a chronic synovial inflammation of the joints, followed by tissue 
destruction at the cartilage junctions.  This leads to deformities and loss of articular 
function.  The classic rheumatoid factor is an IgM antibody which can form complexes 
with normal circulating IgG, as an autoantigen, and are deposited in the joints.  These 
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complexes then activate the complement system, leading to chronic inflammation of the 
joints (Goldsby et al., 2000). 
 Scleroderma.  Scleroderma is a chronic degenerative, but rare, disease that 
affects the skin, internal organs and the vasculature, leading to hardening and tightening 
of the skin and connective tissues.  Scleroderma results from the overproduction and 
accumulation of collagen in connective tissue.  There are also some suggestions of the 
cause of scleroderma in fetal cells’ immune response (Goldsby et al., 2000; Mayo 
Foundation for Medical Education and Research, 2004). 
 
Neoplasia and Cancer 
 T cell cancers involve the uncontrolled proliferation of a clonal population of T 
cells.  Homeostasis in normal tissue is balanced by a process of cellular proliferation and 
cell death regulated by oncogenes and tumor suppressor genes, respectively.  It is 
believed that genetic alterations underlie all cellular and biochemical aberrations 
responsible for the malignant phenotype in human cancer.  Gene alterations include 
serial oncogene activation and tumor suppressor gene inactivation (Tripathy, 2000). 
 The leukemias and lymphomas are malignant tumors or cancers of hematopoietic 
cells of the bone marrow.  T-cell leukemias and lymphomas involve a proto-oncogene 
that has been translocated into the T-cell-receptor genes.  Leukemias proliferate as single 
cells in circulation, whereas lymphomas, Hodgkin’s and non-Hodgkin’s, grow as solid 
tumors within a lymphoid tissue.  Leukemias are classified as acute or chronic according 
to the progression of the disease and cell maturity involved (Goldsby et al., 2000).  Non-
Hodgkin’s lymphoma is less predictable than the Hodgkin’s lymphoma.  Non-Hodgkin’s 
lymphoma is particularly aggressive in HIV-infected patients (Shames and Kishiyama, 
2000). 
 The inducible IL-2R α chain is a component of the high affinity trimeric 
receptor.  It is not expressed on resting cells.  However, it is expressed on the surface of 
abnormal cells in a number of neoplasms of the immune system (Waldmann, 1993). 
9 
  
 While there are many more diseases of the immune system, the ones described 
all share in common the involvement of T cells and the IL-2R in the disease, either at an 
inappropriate level or as the marker of cell activation.  Understanding the involvement of 
the IL-2/IL-2R system in disease provides a framework for the development of 
molecular level therapies to diseases involving T cells. 
 
IL-2/IL-2 RECEPTOR T CELL SYSTEM 
The T cell is one of the components of the immune system.  T cell activation 
begins when the processed and presented foreign protein antigens interact with antigen-
binding receptors on TH cells.  This interaction generates a signal along with an essential 
co-stimulatory signal that up-regulates the expression of the IL-2 and its high affinity 
receptor (IL-2R α chain), leading to proliferation and differentiation of the TH cells.  The 
antigen-specific activated TH cells secrete various cytokines, as a result of cell-specific 
interaction, that induce a specific immunologic response including the differentiation of 
B cells (IL-4, IL-5, IL-6, and IL-10) and the activation of TC cells (IL-2, IFN-γ, and 
TNF-β) and macrophages (Goldsby et al., 2000).  The cytokines have been sited as 
important regulators in T-cell function (Powrie and Coffman, 1993).  Because of its role 
in the regulation/modulation of immune response, the control of TH cells and the 
development of immunomodulatory therapies targeting IL-2/IL-2R proved useful in the 
treatment and prevention of human diseases. 
The T cell receptors are expressed as either the αβ or γδ heterodimers (Lefranc 
and Lefranc, 2001).  The α-subunit contributes to binding of IL-2 and upregulation of 
receptor sensitivity, whereas the β- and γ-subunits contribute mainly to receptor-
mediated internalization and signal transduction (Takeshita et al., 1992; Morris and 
Waldmann, 2000).  Indeed, IL-2 might initially interact with the β chain constitutively 
present on resting T cells.  This binding leads to the rapid induction of genes (i.e. c-myc 
and c-myb) involved in T cell activation and to the expression of genes required for T 
cell progression including Tac forming the high affinity IL-2R (Bich-Thuy et al., 1987).  
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Subtil et al. (1998) detected the β cytosolic domain expressing a unique sorting signal 
involved in targeting the receptor toward degradation.     
The high affinity IL-2R is highly expressed on activated T cells.  It is a 
heterotrimer consisted of three distinct membrane components, IL-2R α chain (Tac, 
CD25, p55, 55 kDa), β chain (CD122, p70 or p75, 70-75 kDa), and γc chain (CD132, 
p64, 64 kDa), associated in a noncovalent manner.  A schematic representation of the 
high affinity IL-2R is given in Figure 2.2 (Minami et al., 1993).  The β and γc chains, the 
chains associate, form the intermediate affinity receptor that is present on resting T cells.  
A comparison of the subunits of the IL-2R forms is provided in Table 2.1 (Goldsby et 
al., 2000).  Indeed, normal cells do not express the IL-2R α in a resting state 
(Waldmann, 1993).  Expression of the α-subunit of the high affinity receptor thus plays 
an important role in T-cell activation and is of clinical importance.  A number of IL-2R 
α related diseases are listed in Table 2.2 (Morris and Waldmann, 2000). 
 
TARGETED DRUG DELIVERY USING IL-2/IL-2 RECEPTOR 
For over 20 years, researchers have been actively investigating means to 
selectively treat diseased cell such as cancers as a means of increasing the therapeutic 
dose delivered to the diseased tissue while minimizing side effects of surrounding 
healthy tissue.  IL-2R expressing abnormal T cells, either cancerous or inappropriately 
stimulated, have been targeted via either the IL-2 ligand or the anti-IL-2R antibody for 
selective elimination of these cells.  Such strategies have been the focus of therapeutic 
intervention associated with lymphoid malignancies, select autoimmune diseases, 
GVHD, and allograft rejection.   
The chimeric or humanized antibodies selected for antibody-targeted therapy 
have increased their clinical usefulness in the treatment of leukemia and lymphoma with 
a favorable pharmacokinetic profile and low immunogenicity (reviewed in van de 
Loosdrecht et al., 2004).  Anti-IL-2R antibodies targeting the IL-2R approved by the US 
Food and Drug Administration are listed in Table 2.3 (reviewed in Waldmann, 2003).  
Strategies targeting the IL-2R with anti-IL-2R antibodies to inhibit its proliferation by 
11 
  
 
 
 
 
 
 
 
 
Figure 2.2.  Schematic representation of IL-2 receptor (Reprinted, with permission, from 
the Annual Review of Immunology, Volume 11 © 1993 by Annual Reviews 
www.annualreviews.org). 
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Table 2.1.  Comparison of the subunits of three IL-2 receptor forms.  The overview on 
association and dissociation constants is also indicated (For a line drawing from KUBY 
IMMUNOLOGY, 4/e by Richard Goldsby, et.al. © 1992, 1994, 1997, 2000 by W. H. 
Freeman and Company. Used with permission). 
 
    Intermediate affinity    High affinity              Low affinity 
      IL-2R βγ      IL-2R αβγ     IL-2R α 
 
Subunit 
composition:      IL-2R β     IL-2R α     IL-2R α 
       IL-2R γ     IL-2R β    
         IL-2R γ 
 
Affinity 
constant (Ka):      107 M     1011 M     108 M 
 
Dissociation 
constant (Kd):      10-9 M                10-11 M     10-8 M 
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Table 2.2.  A listing of some IL-2R α related diseases (Annals of the Rheumatic 
Diseases, 2000, Vol 59, pages i109-i114, reproduced with permission from the BMJ 
Publishing Group). 
 
 
Allograft rejection 
Bone marrow 
Cardiac 
Liver 
Renal 
 
Autoimmune disease 
Aplastic anaemia 
Behcet’s syndrome 
Crohn’s disease 
Giant cell arteritis 
Juvenile rheumatoid arthritis 
Kawasaki disease 
Multiple sclerosis 
Polymalgia rheumatica 
Rheumatoid arthritis 
Sarcoidosis 
Scleroderma 
Sjögren’s syndrome 
Systemic lupus erythematosus 
Vasculitis 
Wegerner’s granulomatosis 
 
Neoplasia 
Acute myelocytic leukaemia 
Anaplastic large cell lymphoma 
Adult T cell leukaemia/lymphoma 
Chronic lymphocytic leukaemia 
Chronic myelocytic leukaemia 
Cutaneous T cell lymphoma 
Mycosis fungoides 
Hairy cell leukaemia 
Hodgkin’s disease 
Non-Hodgkin’s lymphomas (B cell) 
Peripheral T cell lymphomas 
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Table 2.3.  A listing of anti-IL-2R antibodies approved by the US Food and Drug 
Administration (Reprinted with permission from Nature Medicine, Waldmann TA. 
Copyright 2003 by Nature Publishing Group). 
 
Product         Type             Target of action/Condition                                  Approved 
 
Daclizumab   Humanized   CD25 (IL-2R α, Tac) on activated lymphocytes/   1997 
(Zenapax)                           Transplant allograft rejection 
 
Basiliximab   Chimeric      CD25 (IL-2R α) on activated lymphocytes/           1998 
(Simulect)                          Transplant allograft rejection 
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preventing IL-2 binding or using antibody-toxin or -radionuclide conjugates to kill 
targeted cells have been previously investigated (reviewed in Waldmann, 1989; Queen et 
al., 1989; Waldmann, 1991; Waldmann, 1993; Waldmann, 2000).  Waldmann (1991) has 
proposed that the effective immunoconjugates must internalize into the endosome and 
further translocate to the cytoplasm, where the inhibition of protein synthesis occurs.  
Walz et al. (1990) have demonstrated that inhibition of gene and protein synthesis by IL-
2/diphtheria toxin-related fusion protein targeting rIL-2 stimulated T cells appears to be 
dose dependent.  With anti-Tac (anti-CD25), a p55 IL-2R α chain monoclonal antibody, 
the stimulatory effect of IL-2 toxin, under conditions that responded to high IL-2 toxin, 
was mediated by IL-2R binding domain of the fusion protein.  Analogously, with both 
IL-2 toxin and IL-2, stimulation of de novo transcription of a heat shock protein gene in 
phytohemagglutinin (PHA) activated T blasts was shown to have a similar pattern.  The 
γ- and β-emitting radionuclides linked to antibodies suitable for therapy include 213Bi, 
212Bi, 212Pb, 211At, 90Y, and 131I.  Suitable γ-emitting nuclides including 211At, 212Pb, and 
212Bi, which can release high energy emissions over a short distance, are efficient at 
killing the leukemic cells.  A high energy emission assures the destruction of the cell, 
while protecting other nearby healthy cells.  Particularly, the most successful 
radionuclides used in leukemia and lymphoma are the β particles emitted by 131I and 90Y.  
Given that radionuclides act over a short distance and do not need to enter target cells, 
the use of antibody-radionuclide conjugates is effective for their treatment of tumor cell 
antigenic heterogeneity (Waldmann, 2000).  A 90Y-IL-2R anti-Tac has been used 
clinically with some success for treatment of adult T-cell leukemia (Waldmann et al., 
1995).  Conjugates using IL-2 and a portion of the Pseudomonas exotoxin have been 
developed and were found to be effective in mouse models of tissue transplantation, 
tumors expressing the IL-2R, and autoimmune disease (Waldmann, 1993). 
 While there have been many successes with targeted therapies to IL-2R bearing 
cells, in general, internalization and intracellular degradation of the immunotoxin govern 
(and severely limit) the effectiveness of therapy (Press et al., 1988; Braslawsky et al., 
1991; May et al., 1991; Yazdi et al., 1995). 
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ANTISENSE THERAPY AND OLIGONUCLEOTIDE DELIVERY 
The antisense (anti-mRNA) therapeutic approach is the use of sequence-specific 
antisense oligonucleotides to interact with a complementary sequence on a targeted 
mRNA.  This specific base pair interaction leads to the destruction of a targeted mRNA 
and the inhibition of transcription and translation of a specific protein (Gewirtz et al., 
1996; Eichman et al., 2000; Phillips and Gyurko, 1997).  Antisense techniques primarily 
include triple-helix formation with the DNA double helix and hybridization to the newly 
formed RNA to prevent its transcription.  Inhibition of gene expression is mainly 
accomplished by activation of ribonuclease (RNase) H.  RNase H is an endonuclease 
found both in the cytoplasm and the nucleus.  RNase H cleaves the RNA strand of a 
DNA-RNA heteroduplex.  Several cancer-relevant genes known to be important in the 
regulation of apoptosis, cell proliferation, metastasis, and angiogenesis have been 
validated as molecular targets for antisense therapy (see Table 2.4) (reviewed in Jansen 
and Zangemeister-Wittke, 2002).  Antisense therapy could prove to be a useful strategy 
in modulating the function of IL-2R expressing T cells involved in a number of cancers, 
as well as autoimmune and graft versus host diseases. 
Oligonucleotide transfer technology is designed to introduce genetic materials 
into abnormal cells to modulate the expression of a target protein.  Steps involved in 
oligonucleotide transfer include cellular uptake, intracellular trafficking, and (if 
necessary) nuclear translocation.  Ideally, the delivery system should be able to protect 
the oligonucleotide from extracellular degradation and to effect cell-specific delivery to 
a target cell.  A number of investigators have explored the structure and transfection 
parameters of cationic lipids and cationic polymers as a means of increasing efficacy of 
oligonucleotide delivery (Safinya et al., 2002; Holtorf and Mikos, 2002). 
In this work, targeted oligonucleotide delivery to IL-2R bearing cells is examined 
as a means of treating certain diseases including specifically a model T cell cancer.  In 
order to increase the specificity and efficacy of oligonucleotide delivery, we have 
proposed to use a monoclonal antibody for targeting and a positively charged 
polyamidoamine dendrimer as the carrier for the oligonucleotide to the IL-2R bearing T  
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Table 2.4.  A listing of antisense targets (Reprinted with permission from Elsevier 
(Lancet Oncology, 2002, Vol 3, pages 672-683)). 
 
Cell cycle 
Cyclin D 
MYC 
CDKs 
 
Mitogenic pathways growth signalling 
EGFR 
PKA1 
HER2/NEU 
IGF1 
IGFBP2 
BRAF 
PKCα 
RAS/RAF 
 
Impaired apoptosis 
A1 
MCL1 
BCL-2 
BXL-XL 
BCL-W 
IAPs 
Mdm2 
Clusterin 
HSP70 
MITF 
 
Infinite lifespan 
Telomerase 
 
Angiogenesis 
VEGF 
VEGFR 
bFGF 
 
Metastasis 
MMPs 
 
Aberrant gene regulation 
DNA methyltransferase 
Histone deacetylase 
Bold indicates mRNA target for antisense therapy in phase I-III clinical trials.  
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cells.  We believe that the impact of the work presented is in the development of the 
systematic understanding of the role of vehicle properties in the effectiveness of delivery 
of oligonucleotide to cells.  This work will enable the development of appropriate design 
strategies for effective oligonucleotide delivery.  In addition, the work could aid 
development of a clinically useful treatment for autoreactive T cell diseases and be of 
use during tissue transplantation and T cell leukemias, where high expression of the IL-
2R is present. 
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CHAPTER III 
ANTISENSE OLIGONUCLEOTIDE AND RNA INTERFERENCE 
THERAPEUTIC INTERVENTION AND STABILITY 
 
INTRODUCTION 
The antisense (anti-mRNA) therapeutic approach is the use of sequence-specific 
antisense oligonucleotides (13-25 bases, single-stranded RNA or DNA molecules) to 
interact with complementary sequence on a targeted mRNA.  This specific base pair 
interaction leads to the destruction of a targeted mRNA and the inhibition of 
transcription and translation of a specific protein (Gewirtz et al., 1996; Eichman et al., 
2000; Phillips and Gyurko, 1997).  Antisense techniques primarily include triple-helix 
formation with the DNA double helix and hybridization to the newly formed RNA to 
prevent its transcription.   
Oligonucleotides, in their natural form, have a phosphodiester (PO-) backbone 
that is readily degraded by serum or cellular (exo- and endo-) nucleases (Phillips and 
Gyurko, 1997; Toth et al., 2002).  A schematic of typical nucleases is provided in Figure 
3.1 (Mishra, 2002).  Phosphorothioate (PS-) analogs, containing a single sulfur atom 
replacing an oxygen atom in a nonbridging position with phosphorus, have become 
attractive as the modification of choice due to their affinity for targeted mRNA, greater 
resistance to nuclease degradation due to chiral internucleotide linkages, and activation 
of ribonuclease (RNase) H-mediated RNA degradation.  However, the increased 
oligonucleotide-protein (i.e. nucleic acid polymerases) binding, polyanionic and immune 
stimulatory characteristics of PS-analog are believed to affect their specificity and 
mechanism of actions (Phillips and Gyurko, 1997; Roush, 1997; Agrawal, 1999). 
RNA-mediated interference (RNAi) is emerging as a groundbreaking discovery 
in the field of nucleic acid-based gene control.  RNAi relies on the in vivo generation of 
short interfering RNA (siRNA) as an effector of targeted gene silencing at the 
posttranscriptional level.  Short interfering RNA is a double-stranded RNA fragment of 
approximately 21-23 base pairs produced from the long double-stranded (ds)RNA  
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A 
 
B 
 
 
C 
Figure 3.1.  Schematic of nucleases.  (A) Phosphodiesterase.  (B) DNase.  (C) 
Restriction endonuclease (Reprinted with permission of John Wiley & Sons, Inc from 
Nucleases: Molecular Biology and Applications, by Mishra NC, 2002, Wiley-
Interscience, New Jersey. Copyright © 2002 by John Wiley & Sons, Inc). 
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molecule.  In the siRNA pathway, long dsRNA is cleaved by the RNase III family 
member, called Dicer, into siRNAs in an ATP-dependent reaction.  These siRNAs are 
then incorporated into the RNA-induced silencing complex (RISC), a second 
endoribonuclease complex.  The duplex siRNA is unwound, leaving the encoded 
antisense strand to guide RISC to its complementary sequence of targeted mRNA for 
cleavage (Zamore, 2002; reviewed in Dykxhoorn et al., 2003).  Recently, Gautherot and 
Sodoyer (2004) have proposed the multi-model strategy for design and optimization of 
siRNA sequences.  Interestingly, siRNA has now been used as a potential therapeutic 
tool to target specific oncogenes (Damm-Welk et al., 2003) in mammalian cancer cell 
lines (Kittler and Buchholz, 2003).  Furthermore, Bertrand et al. (2002) have reported 
that siRNA appears to be more efficient than antisense oligonucleotide, likely due to its 
higher resistance to nuclease degradation. 
In the work described here, we examined the relative stability of 
oligonucleotides, both phosphodiester and phosphorothioate analogs, against 
intracellular and extracellular nucleases using a biological activity assay (toxicity) and 
an HPLC method.  We describe the development of an HPLC method to measure the 
rate of oligonucleotide degradation in the presence and absence of dendrimer.  We 
identify the rate of intracellular degradation to be much greater than extracellular 
degradation. 
 
MATERIALS AND METHODS 
Materials   
Synthetic wholly PO- and PS-linked oligonucleotides molecular weights 5,485 
and 5,773, respectively, were purchased from Gene Technologies Laboratory, Institute 
of Developmental and Molecular Biology, Texas A&M University (College Station, TX) 
and Sigma-Genosys (The Woodlands, TX).  Commercially available PAMAM 
dendrimers were purchased from Aldrich (Milwaukee, WI) and used without further 
purification.  Cell culture reagents were purchased from GibcoBRL (Grand Island, NY).  
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) was purchased 
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from Pierce (Rockford, IL).  All other chemicals, unless otherwise specified, were 
obtained from Sigma (St. Louis, MO). 
 
Oligonucleotide   
Single-stranded 18-bp PO- and PS-oligonucleotides to the 63-kDa form of 
phosphodiesterase 1 (PDE1B1) were synthesized (see Figure 3.2).  The PS-
oligonucleotide was modified at every base position.  This oligonucleotide was targeted 
against the translation initiation region of the human B-lymphoblastoid cell line mRNA 
encoding PDE1B1, which is selectively expressed in leukemic and actively growing 
lymphocytes (Jiang et al., 1996).  A sequence was manipulated and homology searches 
were performed against nucleic acid sequence database Biology Workbench Version 3.2, 
University of California San Diego, for the possibility of cross-reaction. 
 
Oligonucleotide Solution Preparation  
Stock solutions of 10-fold µM were prepared by dissolving the oligonucleotides 
in TE (10 mM Tris, 1 mM EDTA, pH 8.0).  The stock solutions were diluted in 
phosphate buffer saline (PBS, 13.67 mM NaCl, 2.68 mM KCl, 10 mM Na2HPO4, 1.76 
mM KH2PO4, pH 7.2) to the concentrations used in the experiment. 
 
Cell Culture   
Mouse HB-8555 hybridoma cells (ATCC, Rockville, MD) were cultured in a 
humidified 5% (v/v) CO2/air environment at 37°C in RPMI supplemented with 10% 
(v/v) FBS, 2 mM L-glutamine, 10 mM HEPES, 4.5 g/L glucose, 1 mM sodium pyruvate, 
0.025 mM 2-mercaptoethanol, 100 U/mL penicillin, 100 µg/mL streptomycin, and 2.5 
µg/mL amphotericin B (pH 7.4).  Culture supernatant was collected every 4 to 5 days 
and stored at 4°C for further antibody purification.  Human T-cell leukemia TIB-152 
Jurkat cells (ATCC, Rockville, MD) were cultured in a humidified 5% (v/v) CO2/air 
environment at 37°C in RPMI supplemented with 10% (v/v) FBS, 10 mM HEPES, 4.5 
g/L glucose, 2 mM sodium pyruvate, 100 U/mL penicillin, 100 µg/mL streptomycin, and 
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Oligonucleotide 
 
5' GGA CAG CTC CAT GCT CAG 3' 
 
Oligonucleotide Structures 
 
PO- 
 
PS- 
 
Target PDE1B1 Sequence 
 
5' gctrgtccmygccagccgcagaccgtggctgagc ATG GAG CTG TCC CCC CGC … 3' 
   ----------- untranslated region ----------- ---------- open reading frame ----------  
r = A or G 
m = A or C 
y = C or T 
 
Figure 3.2.  Schematic of PO- and PS-oligonucleotide sequences used in the study. 
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2.5 µg/mL amphotericin B (pH 7.4).  For the oligonucleotide toxicity experiments, cells 
were plated at densities ranging from 5 to 6 x 105 cells/well in 96 well plates. 
 
IL-2 Receptor Monoclonal Antibody Purification  
   Anti IL-2R (CD25) monoclonal antibody was purified from cell culture 
supernatant by affinity chromatography using a protein A Sepharose 4 Fast Flow column 
(Pharmacia, Piscataway, NJ) via standard techniques (Harlow and Lane, 1988; Montage 
Antibody Purification Kit and Spin Columns with PROSEP-A Media User Guide, 
Millipore, Bedford, MA).  The culture supernatant from HB-8555 cells was filtered 
through a 0.22-0.45 µm pore size, 47 mm diameter filter (Millipore, Bedford, MA) and 
diluted 1:1 (v/v) in a binding buffer (1.5 M glycine/NaOH, 3 M NaCl, pH 9.0) before 
loading.  The column was washed with 10 bed volumes of binding buffer to remove 
unbound contaminants.  The bound antibody was then eluted with an elution buffer (0.1 
M sodium citrate, pH 5.5). 
   The pH of purified antibody was neutralized using a 1:20 (v/v) neutralization 
buffer (1M Tris/HCl, pH 9.0).  The antibody solution was concentrated using the 
Microcon ultra centrifugal filter device with a 30000 molecular weight cut off membrane 
(Millipore, Bedford, MA).  The concentration and purity of antibody were then 
determined by the absorbance reading at 280 nm (1 OD is approximately equal to 0.8 
mg/mL) and SDS PAGE using the pHastgel system (Pharmacia, Piscataway, NJ), 
respectively.  An antibody was stored at -20°C until use. 
 
Antibody Dendrimer Conjugation  
Solutions of dendrimer and EDC were mixed in a conjugation buffer (0.1 M 
MES, pH 5.0) in a molar ratio of 1:1.  An antibody was added to the complex mixture 
and rotated at 60 revolutions per minute at room temperature for 3 hours.  An antibody 
dendrimer conjugate was then purified on a PD-10 desalting column (Pharmacia, 
Piscataway, NJ) in phosphate buffer saline (PBS, 13.67 mM NaCl, 2.68 mM KCl, 10 
mM Na2HPO4, 1.76 mM KH2PO4, pH 7.2), and the first peak containing antibody was 
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collected.  Unreacted reagents were further removed via ultra filtration through a 30000 
molecular weight cut off membrane (Millipore, Bedford, MA).  The protein content was 
then measured with the absorbance readings at 280 nm and the BCA assay (Walker, 
2002) to calculate the degree of conjugation. 
 
MTT Reduction Assay 
Jurkat cell viability was measured using the 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-
diphenyl-2H-tetrazolium bromide (MTT) reduction assay (Pollack et al., 1995).  The 
oligonucleotide samples with or without an antibody dendrimer conjugate were 
incubated with the cells for various lengths of time, after which time MTT was added to 
the culture medium to yield a final MTT concentration of 0.5 mg/mL.  Cells were 
incubated with the MTT for 4 hours in a CO2 incubator after which time 100 µL of a 
5:2:3 N, N-dimethylformamide (DMF): sodium dodecyl sulfate (SDS): water solution 
(pH 4.7) was added to dissolve the formed formazan crystals.  Then, after 20 hours of 
incubation in a humidified CO2 incubator, the MTT absorbance was measured using an 
Emax Microplate reader at 585 nm (Molecular Devices, Sunnyvale, CA).  Viability was 
reported relative to control cells unexposed to the oligonucleotides with or without an 
antibody dendrimer conjugate. 
 
Conditioned Medium 
Conditioned medium was taken from the 3-day Jurkat cells.  Cells were removed 
by centrifugation (500 rpm, 8 min), and the resulting supernatant was sterile filtered 
using a 0.2 µm syringe filter unit (Nalge Nunc International Corporation, Rochester, 
NY).  The total protein content was measured with the BCA assay (Walker, 2002). 
 
Nuclease Containing Cellular Extract 
Jurkat cells at a density of 8 x 106 cells/mL were collected by centrifugation (500 
rpm, 8 min) and then thoroughly washed twice with cold phosphate buffer saline.  
Subsequently, they were resuspended in1.2 mL of low ionic-strength phosphate buffer (5 
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mM Na2HPO4, 0.88 mM KH2PO4, pH 7.2) and sonicated using an ultrasonic bath-
cleanser (Cole-Parmer, Vernon Hills, IL) for 2 minutes.  Cellular debris was then 
removed by centrifugation at 17400 x g, 4°C, 20 min.  The total protein content in the 
cell lysate was measured with the BCA assay (Walker, 2002). 
 
Oligonucleotide Degradation Assay 
Stability was assayed by incubating 30 µM PO-oligonucleotides in phosphate 
buffer saline (PBS, 13.67 mM NaCl, 2.68 mM KCl, 10 mM Na2HPO4, 1.76 mM 
KH2PO4, pH 7.2), RPMI containing 10% (v/v) heat-inactivated FBS, conditioned 
medium and the cell lysate at 37°C in a total volume of 100 µL in a microcentrifuge 
tube.  After the specified time, the hydrolysis products were identified by an UltiMate™ 
capillary HPLC system with UV detection at 260 nm (LC Packings, BV, Dionex, 
SanFrancisco, CA) using a Superdex Peptide PC 3.2/30 (bed dimensions: 3.2 x 300 mm) 
gel filtration column (Pharmacia, Piscataway, NJ).  HPLC conditions are given in the 
figure captions.  The relative concentrations of full-length oligonucleotide or hydrolysis 
products were then quantified by the peak areas in the chromatograms.  The peak area 
was calculated as the total sum of 1 1 2
1 1 2
mAU mAU mAU mAU
t t t t
− −=− − . 
 
Complex Degradation Assay   
To evaluate the ability of the dendrimer to protect the oligonucleotide from 
degradation, the complex at a molar ratio (= molar fraction of oligonucleotide/molar 
fraction of dendrimer) equivalent to 1:3 was formed by mixing the oligonucleotide with 
the dendrimer at a concentration of 10 and 30 µM, respectively, in Tris buffer saline 
(TBS, 13.67 mM NaCl, 2.68 mM KCl, 25 mM Tris, pH 8.0).  The complex mixture was 
then rotated at 60 revolutions per minute at room temperature for 2 hours.  Stability was 
assayed by incubating the complexes in the cell lysate at 37°C in a total volume of 100 
µL in a microcentrifuge tube.  After the specified time, urea, n-octyl-β-D-
glucopyronoside, or 1 N NaOH was gradually added in order to dissociate the 
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complexes.  Gradient separation of oligonucleotides and dendrimers was performed 
using an UltiMate™ capillary HPLC system with UV detection at 215, 260, and 280 nm 
(LC Packings, BV, Dionex, SanFrancisco, CA) using a ProPac WCX-10G (bed 
dimensions: 4 x 50 mm) guard column (Dionex, Sunnyvale, CA).  HPLC conditions are 
given in the figure captions.  The first peak containing oligonucleotide was collected, 
and the fraction was then identified by HPLC using a Superdex Peptide PC 3.2/30 (bed 
dimensions: 3.2 x 300 mm) gel filtration column (Pharmacia, Piscataway, NJ). 
 
Data Analysis  
All data were presented as the mean ± standard deviation of n independent 
observations.  To determine whether a treatment data set was significantly different than 
a control data set, the p-value was calculated by a two-sample, two-sided t-test 
comparing the mean to the mean of the control. 
 
Model and Parameter Estimation   
The degradation of oligonucleotide was assumed to be first order in 
oligonucleotide and protein (or nuclease) content of the medium.  The following system 
of equations describes the mass action kinetics and exponential decay of oligonucleotide 
nuclease degradation (Equation 3.1 and Equation 3.2). 
app
dD k D
dt
= −         (3.1) 
0
0 0
appk t kE tD D e D e− −= =       (3.2) 
where D is the amount of full-length oligonucleotide at time t, D0 indicates the amount 
of full-length oligonucleotide at t = 0, E0 represents the total protein content, and the 
coefficient k is the rate constant for the decay of full-length oligonucleotide.  We then 
estimated parameter k of Equation 3.2 using SigmaPlot version 8.02 software (SPSS 
Inc., Chicago, IL). 
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RESULTS 
Successful antisense or siRNA therapy depends upon the delivery of intact 
oligonucleotide to the target location inside the cell.  Unmodified PO-oligonucleotide is 
readily degraded by serum or nucleases (Kandimalla et al., 1997).  We performed a 
series of experiments such that we could infer the stability of oligonucleotides with 
different backbone chemistries and in the presence and absence of dendrimer delivery 
vehicle. 
 
Oligonucleotide Toxicity Experiments   
 We used an antisense sequence reported to induce toxicity in model leukemia cell 
lines (Jiang et al., 1996), delivered the oligonucleotide to cells, and measured viability 
after 24 and 48 hours.  As seen in Figure 3.3, oligonucleotides with the phosphodiester 
backbone had minimal effect on cell viability; however, PS-oligonucleotides when 
added to cells resulted in a significant decrease in cell viability (Figure 3.4).  These 
results suggested that naked PO-oligonucleotide was being degraded prior to its arrival 
at the cell specific location needed to induce toxicity in the leukemia cell line.  
Therefore, to test if an IL-2R targeted delivery vehicle would increase oligonucleotide 
delivery and toxicity, cells were treated with oligonucleotides in the presence of an 
antibody dendrimer conjugate.  As shown in Figure 3.5, toxicity after treatment with PS-
oligonucleotides in the presence of the delivery vehicle was only marginally greater than 
toxicity of PS-oligonucleotide alone.  In addition, the delivery vehicle alone (at zero 
concentration of PS-oligonucleotide) was as toxic as the PS-oligonucleotide. 
 Given the relatively low toxicity of the antisense oligonucleotide in the model 
leukemia cell line used in these experiments, it was difficult to assess changes in stability 
of oligonucleotide with backbone modification or in the presence or absence of the 
delivery vehicle; therefore, a more direct method was chosen to examine oligonucleotide 
stability. 
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Figure 3.3.  PO-oligonucleotide toxicity experiment.  The toxicity of PO-
oligonucleotide was determined as a function of its concentrations.  The data are 
reported as the fraction of the viability of the cells incubated with the PO-
oligonucleotides for (A) 24 and (B) 48 hours relative to the viability of control cells 
unexposed to the PO-oligonucleotides.  The mean + standard deviation of 7-8 
determinations are presented.  For each presented, * indicates measurement is 
significantly different than for control cells (p<0.05). 
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Figure 3.4.  PS-oligonucleotide toxicity experiment.  The toxicity of PS-oligonucleotide 
was determined as a function of its concentrations.  The data are reported as the fraction 
of the viability of the cells incubated with the PS-oligonucleotides for (A) 24 and (B) 48 
hours relative to the viability of control cells unexposed to the PS-oligonucleotides.  The 
mean + standard deviation of 4-6 determinations are presented.  For each presented, * 
indicates measurement is significantly different than for control cells (p<0.05). 
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Figure 3.5.  Toxicity of PS-oligonucleotide in the presence of antibody dendrimer 
conjugate.  The toxicity of PS-oligonucleotide in the presence of an antibody dendrimer 
conjugate was determined as a function of oligonucleotide concentrations.  The data are 
reported as the fraction of the viability of the cells incubated with the PS-
oligonucleotides in the presence of an antibody dendrimer conjugate for (A) 24 and (B) 
48 hours relative to the viability of control cells unexposed to the PS-oligonucleotides 
with the conjugate.  The mean + standard deviation of 5-6 determinations are presented.  
For each presented, * indicates measurement is significantly different than for control 
cells (p<0.05). 
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Oligonucleotide Degradation Assay and Parameter Estimation   
HPLC analysis was used to identify hydrolysis products formed due to nuclease 
degradation.  Representative chromatograms of PO-oligonucleotide and hydrolysis 
products in phosphate buffer saline (Figure 3.6A), in fresh medium (Figure 3.7A), in 
conditioned medium (Figure 3.8A), and in cell lysate (Figure 3.9A) are shown as a 
function of time exposure to the medium.  The relative concentrations of intact 
oligonucleotides, calculated from peak areas of chromatograms, are shown as a function 
of incubation time in buffer, fresh medium, conditioned medium, and cell lysate, in 
Figures 3.6B, 3.7B, 3.8B, and 3.9B, respectively.  As seen in Figure 3.6, little or no 
degradation of oligonucleotide occurred in the phosphate buffer saline solution.  These 
results establish that the oligonucleotide is stable in the absence of nucleases in our 
study.  In Figures 3.7 and 3.8, the rate of degradation of oligonucleotides in fresh and 
conditioned medium can be seen.  Degradation rates were similar in fresh and 
conditioned medium, and were somewhat modest.  In contrast, oligonucleotide 
degradation in cell lysate was considerable (Figure 3.9).  First order rate constants for 
degradation were estimated in the various medium from data presented in Figures 3.6-
3.9.  A summary of estimated rate constants, presented in Table 3.1, indicates clear 
differences in degradation between intra- and extracellular environments. 
 
Complex Degradation Assay  
 The ability of dendrimer to protect the oligonucleotide against nuclease 
degradation is of great interest.  Thus, we were interested in evaluating the ability of the 
dendrimer delivery vehicle to protect the oligonucleotide from degradation in both intra- 
and extracellular environments.  In order to accomplish this goal, we needed to first 
develop an HPLC method for the separation of the oligonucleotide and dendrimer prior 
to measurement of hydrolysis products from oligonucleotide degradation. 
 A cationic-exchange HPLC method was evaluated for the separation of the 
oligonucleotide and the dendrimer.  It should be noted that, in our study, complexing the 
oligonucleotide and generation 3.0 dendrimer at a molar ratio equivalent to 1:1 resulted 
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4 hours 
 
 
Figure 3.6.  Degradation patterns of PO-oligonucleotides in phosphate buffer saline pH 
7.2.  Degradation was monitored by HPLC.  (A) Representative HPLC chromatograms 
of oligonucleotides as a function of incubation time; (B) Oligonucleotide expressed in 
units of relative concentration is plotted versus incubation time.  HPLC was performed 
with a 20-µL sample loop using 20 mM phosphate buffer containing 250 mM NaCl, pH 
7.2 at a flow rate of 0.1 mL/min.  The buffer solution was filtered and degassed by 
vacuum filtering using a 0.2 µm pore size, 47 mm diameter filter composed of nylon 66 
(Rainin, Ridgefield, NJ).  Sixty µL of samples were injected and the eluate absorbance 
was monitored at 260 nm. 
 
 
 
 
0
200
400
600
800
0 20 40 60 80
Time (minutes)
m
A
U
 a
t 2
60
 n
m
0
200
400
600
800
0 20 40 60 80
Time (minutes)
m
A
U
 a
t 2
60
 n
m
34 
  
8 hours 
 
12 hours 
 
24 hours 
 
 
Figure 3.6.  (Continued) 
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Figure 3.6.  (Continued) 
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Figure 3.7.  Degradation patterns of PO-oligonucleotides in fresh medium.  Degradation 
was monitored by HPLC.  (A) Representative HPLC chromatograms of oligonucleotides 
as a function of incubation time; (B) Oligonucleotide expressed in units of relative 
concentration is plotted versus incubation time.  HPLC was performed with a 20-µL 
sample loop using 20 mM phosphate buffer containing 250 mM NaCl, pH 7.2 at a flow 
rate of 0.1 mL/min.  The buffer solution was filtered and degassed by vacuum filtering 
using a 0.2 µm pore size, 47 mm diameter filter composed of nylon 66 (Rainin, 
Ridgefield, NJ).  Sixty µL of samples were injected and the eluate absorbance was 
monitored at 260 nm.  PO-oligonucleotides in fresh medium were tested for stability.   
A BCA assay was performed in order to quantify the protein concentration.  The total 
protein concentration in the fresh medium was 22.14 mg/mL.  Measurements were 
performed in duplicate (sample discrepancies were within 24 mAU·minute units). 
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Figure 3.7.  (Continued) 
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Figure 3.7.  (Continued) 
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Figure 3.8.  Degradation patterns of PO-oligonucleotides in conditioned medium.  
Degradation was monitored by HPLC.  (A) Representative HPLC chromatograms of 
oligonucleotides as a function of incubation time; (B) Oligonucleotide expressed in units 
of relative concentration is plotted versus incubation time.  HPLC was performed with a 
20-µL sample loop using 20 mM phosphate buffer containing 250 mM NaCl, pH 7.2 at a 
flow rate of 0.1 mL/min.  The buffer solution was filtered and degassed by vacuum 
filtering using a 0.2 µm pore size, 47 mm diameter filter composed of nylon 66 (Rainin, 
Ridgefield, NJ).  Sixty µL of samples were injected and the eluate absorbance was 
monitored at 260 nm.  PO-oligonucleotides in conditioned (taken from 3-day cells) 
medium were tested for stability.  A BCA assay was performed in order to quantify the 
protein concentration.  The total protein concentration in the conditioned medium was 
18.39 mg/mL.  Measurements were performed in duplicate (sample discrepancies were 
within 24 mAU·minute units). 
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Figure 3.8.  (Continued) 
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Figure 3.8.  (Continued) 
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Figure 3.9.  Degradation patterns of PO-oligonucleotides in cell lysate.  Degradation 
was monitored by HPLC.  (A) Representative HPLC chromatograms of oligonucleotides 
as a function of incubation time; (B) Oligonucleotide expressed in units of relative 
concentration is plotted versus incubation time.  HPLC was performed with a 20-µL 
sample loop using 20 mM phosphate buffer containing 250 mM NaCl, pH 7.2 at a flow 
rate of 0.1 mL/min.  The buffer solution was filtered and degassed by vacuum filtering 
using a 0.2 µm pore size, 47 mm diameter filter composed of nylon 66 (Rainin, 
Ridgefield, NJ).  Sixty µL of samples were injected and the eluate absorbance was 
monitored at 260 nm.  PO-oligonucleotides in cell lysate were tested for stability.   
A BCA assay was performed in order to quantify the protein concentration.  The total 
protein concentration in the cell lysate was 0.3814 mg/mL.  Measurements were 
performed in duplicate (sample discrepancies were within 32 mAU·minute units). 
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Figure 3.9.  (Continued) 
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Figure 3.9.  (Continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
  
Table 3.1.  Summary of exponential decay rate constants of PO-oligonucleotide 
obtained in degradation experiments. 
 
Treatment                      k 
                       (mg/mL)-1 hr-1 
Phosphate Buffer Saline pH 7.2                   0 
 
Fresh Medium                           0.0002 ± 0.00003 
 
Conditioned Medium                     0.0001 ± 0.00004 
 
Cell Lysate                                                                       0.0121 ± 0.0011 
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in complex aggregation.  Therefore, a complex of 3-fold molar excess dendrimer in TBS 
at pH 8.0 was used.  The electrostatic interaction between oppositely charged species is a 
process which can be reversed under the increase in ionic strength of the physiological 
environment, pH change, and dilution.  In this work, the separation of oligonucleotide 
and generation 3.0 dendrimer was achieved on a cationic-exchange guard column using 
a linear salt gradient.  The representative chromatogram in Figure 3.10 shows fully 
resolved peaks of oligonucleotide and generation 3.0 dendrimer.  It is important to note 
that almost 100% of the oligonucleotide was separated from the complex. 
Considerable aggregation of discrete particles was observed in our study.  We 
incubated the dendrimer-oligonucleotide complex in cell lysate in order to examine the 
ability of the dendrimer to reduce the rate of degradation of the oligonucleotide in the 
intracellular environment; however, incubating the complexes in lysate produced 
aggregates that are easily visible to the unaided eye during incubation over several 
hours.  We further examined the aggregation products of the dendrimer complex 
incubated in the cell lysate such that we could eventually analyze the hydrolysis products 
of the oligonucleotide formed in this environment.  Because this aggregation 
phenomenon is not as well documented, several attempts had been made in order to 
dissolve the pellets.  The gradually small addition of a base solution to the mixture over 
the monitoring of change of pH or the addition of known detergents, such as urea and n-
octyl-β-D-glucopyronoside, all resulted in oligonucleotide degradation or non-dissolved 
complexes, respectively.  In particular, it is important to note that the amount of intact 
oligonucleotide was completely degraded at pH 11-13, indicating that the basic pH is 
responsible for degradation (data not shown).  Inability to dissolve the resulting 
aggregates suggested that the complexes and cell lysate have an inherent tendency 
toward aggregation under physiological buffer conditions.  Therefore, a more complex 
model of aggregation and/or colloid behavior may be required to describe how cell 
lysate mediates aggregation of the dendrimer complex. 
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Figure 3.10.  Gradient separation of generation 3.0 dendrimer and PO-oligonucleotide 
by HPLC in cationic-exchange conditions.  HPLC was performed with a 250-µL sample 
loop using a binary buffer system composed of buffer A: 20 mM phosphate buffer, pH 
7.0 and buffer B: 20 mM phosphate buffer containing 2 M NaCl, pH 6.8 at a flow rate of 
0.5 mL/min.  (A) The gradient started at 0-50% B for 0-15 min; it reached 50% B for 15 
min.  (B) It was then increased to 50-100% B for 0-15 min; it reached 100% B for 15 
min.  The absorbance at 215, 260 and 280 nm is plotted versus time.  The buffer solution 
was filtered and degassed by vacuum filtering using a 0.2 µm pore size, 47 mm diameter 
filter composed of nylon 66 (Rainin, Ridgefield, NJ).  Fifty µL of samples were injected 
and the eluate absorbance was monitored at 215, 260, and 280 nm.  Note that almost 
100% of the oligonucleotide, the first peak in (A), was separated from the complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
-10
90
190
290
390
490
0 1 2 3 4
Time (minutes)
m
AU
0.0
0.2
0.4
0.6
0.8
1.0
Na
Cl
 (M
)
215 nm
280 nm
260 nm
48 
  
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10.  (Continued) 
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DISCUSSION 
Recent rapid development in functional genomics has led to a rapid expansion in 
identifying defective genes that cause a variety of human diseases.  Gene therapy and 
antisense approaches have emerged as novel therapeutics and have provided an effective 
treatment to inhibit synthesis of those defective gene products as a cure for diseases.  
Antisense oligonucleotides hybridize with complementary cellular DNA or RNA 
sequences and inhibit a sequence-specific gene expression either in the nucleus or in the 
cytoplasm, resulting in repression of protein expression. 
Several investigators have proposed a conceptual cellular delivery system in 
which uptake of oligonucleotides is driven through an energy-dependent mechanism.  
Endocytosis (receptor-mediated, adsorptive and fluid-phase or pinocytosis) and non-
endocytosis associated with specific proteins are believed to be involved in the cell 
membrane transport and cellular internalization of oligonucleotides (Cotten et al., 1990; 
Gewirtz et al., 1996; Wu-Pong et al., 1997; Garcia-Chaumont et al., 2000; Lou et al., 
2001; and others).  Upon internalization, endosomal compartments undergo continuous 
acidification from the initial cell surface pH (~7) to that found in lysosomes (~4) through 
the action of ATP-dependent proton pumps acting in conjunction with other ion 
transporters found in the membrane.  Endocytosed oligonucleotides then escape the 
endosomal and lysosomal compartments and bind to the mRNA targets for transcription 
(Phillips and Gyurko, 1997; Varga et al., 2000).  Upon entering the nucleus, 
oligonucleotides are rapidly bound to the nuclear matrix in the process of transcription 
(Shi and Hoekstra, 2004).  The progress and ultimate success in any of these steps 
associated with delivery of oligonucleotide to target site within the cell and reduced 
expression of the protein of interest is highly dependent upon the stability of the 
oligonucleotides in both extracellular and intracellular compartments. 
In this study, we delivered single-stranded DNA in the form of PO- and PS-
antisense oligonucleotides to specific to the translation initiation region of the human B-
lymphoblastoid cell line mRNA encoding PDE1B1, which is selectively expressed in 
leukemic and actively growing lymphocytes (Jiang et al., 1996) without cross-reaction 
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with other sequences in the human genome.  We first proposed to examine stability of 
oligonucleotides as function of backbone substitution and presence or absence of 
dendrimer delivery vehicle by examining the toxicity of the oligonucleotide on the 
model leukemia like cell line.  We expected backbone substitution and use of the 
delivery vehicle to enhance toxicity but enhancing stability and facilitating the 
internalization of the oligonucleotide.  However, unlike the previous study we cited, the 
selected oligonucleotides with and without an IL-2R targeted delivery vehicle did not 
significantly alter cell viability.  These results have two major implications: (1) there 
was a problem in one or more of the many steps necessary for effective oligonucleotide 
delivery, protein expression reduction, and subsequent loss of cell viability that was 
expected; and (2) specific experiments will be needed to assess the progress of each 
individual step in oligonucleotide delivery and protein expression reduction.  
There are several possible explanations for why the antisense oligonucleotide 
chosen for these experiments, which was reported by others to lead to a reduction in 
viability of a human B lymphoblastoid cell line, did not lead to significant reduction in 
viability of our model leukemia line (Jurkat cells).  We might have selected a less 
efficient sequence for Jurkat cells or that the suppression of gene expression by that 
sequence is transient.  There may be a possibility that the cells used in our study are 
difficult to transfect.  Moreover, when naked oligonucleotides are added to cells, they 
may not permeate well across the plasma membrane, most likely due to their negative 
charge against the negatively charged plasma membrane.  In addition, the molecular 
weight of oligonucleotides used in our study far exceeds 1000 Da which could possibly 
cause a significant delivery problem.  Previous studies have demonstrated that PS-
oligonucleotides appeared to enter the endosomes, whereas the PO-derivatives showed 
relatively short half-lives and could undergo efflux from the cell prior to acidification 
(Tonkinson and Stein, 1994). 
While we presented toxicity data for antisense directed against PDE1B1, we have 
tried other cellular targets (cyclin D1 and cyclin B1) and approaches for delivery, 
summarized in Table 3.2.  The cyclins are necessary for cell proliferation, and their 
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Table 3.2.  Summary of the toxicities of oligonucleotide and siRNA in the presence and 
absence of the delivery vehicle.  The data are reported as the fraction of the viability of 
the cells incubated with the oligonucleotides and siRNA for 48 and 24 hours, 
respectively, in the presence and absence of the delivery vehicle relative to the viability 
of untreated control cells. 
  
mRNA target Sequence Concentration Delivery 
vehicle 
Fraction of 
viability 
 
Cyclin D1 
 
 
Cyclin B1 
Oligonucleotide
 
 
siRNA 
33.3 µM 
16.7 µM 
 
75 nM 
75 nM 
None 
Dendrimer 
 
None 
Oligofectamine 
0.75 ± 0.06 
0.71 ± 0.25 
 
0.93 ± 0.03 
0.84 ± 0.05 
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inhibition should lead to either a reduction in proliferation or loss of viability in cells.  
Under similar concentration ranges (up to 30 µM), no more than 20% reduction in cell 
proliferation was ever observed.  We also compared the use of antisense 
oligonucleotides and siRNA, which should act on their cellular targets via different 
mechanisms.  We did not have significant success with either approach.  We also 
compared delivery with lipofectamine (a commercially available transfection agent) 
versus naked siRNA, with limited differences in proliferation; 7% reduction in 
proliferation with naked siRNA versus 20% reduction in proliferation with 
lipofectamine.  These results highlight the difficulty in use of antisense and siRNA in 
leukemia treatment.  But even more, they highlight the need for independent 
measurements of the different mechanistic steps associated antisense or siRNA delivery 
such that effective oligonucleotide therapies can be engineered. 
 Antisense PO-oligonucleotides are susceptible to degradation via the endocytic 
route by exo- and endonucleases present in serum and some intracellular compartments.  
Studies by Hudson et al. (1996) have proven that oligonucleotides exposed to a mixture 
of rat liver lysosomal enzymes rapidly degraded as assessed via laser densitometry of 
autoradiography and reverse-phase HPLC.  The rate taken for 50% degradation was 
found to be approximately 30-50 minutes.  These results indicate that the lysosomal 
compartment is a major site of intracellular degradation. 
 Here, we reported the development of a size exclusion HPLC analytical 
technique for measurement of the stability of oligonucleotides.  To our knowledge, we 
are the first group to develop the cationic-exchange HPLC method, as an analytical tool, 
for the separation of oligonucleotide and dendrimer.  The use of HPLC is considered 
desirable for monitoring stability.  By using HPLC, we were able to examine the 
portions of the oligonucleotide based on the difference in size and/or molecular mass 
that were degraded during incubation and, thus, give more detailed information on 
reaction products.  Previous studies have evaluated the enzymatic degradation patterns 
of oligonucleotides by capillary gel electrophoresis along with mass spectrometry 
(MALDI-MS) to get a better insight on the cleavage reactions (Bruin et al., 1995). 
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 Our in vitro results suggest that the naked oligonucleotide, not complexed with 
dendrimer vehicle, is more stable extracellularly than in the intracellular environment (in 
cell lysate).  Indeed, the proteolytic enzymes and nucleases are rich in the lysosomal 
compartment.  Moreover, while not shown, we have revealed that PS-oligonucleotides 
exhibit more resistance to nucleases than the PO-derivatives. 
 Ample evidence exists that suggests that DNA masked by the polycations could 
be protected against nuclease degradation.  In one study, complexation of the plasmid 
DNA to dendrimer at excess positive charges appeared to be resistant to nucleases, 
presumably by altering the accessibility of the DNA to nucleases.  It is interesting to 
note that the binding of plasmid DNA to dendrimer only altered its secondary and 
tertiary structure without fragmentation of the DNA (Bielinska et al., 1997).  
Furthermore, conjugation of the oligonucleotide with an anionic dendrimer improved its 
stability against serum nucleases, possibly due to steric hindrance of the branched 
dendrimer (Hussain et al., 2004).  Another study has shown that poly(ethylene glycol)-
poly-L-lysine-based complexes as assessed via electrophoresis exhibited complete 
protection of DNA from nucleolytic degradation.  Particularly, its increase in protection 
was found to depend on the molecular weight of the poly-L-lysine used (Dash et al., 
1997).  De Oliveira et al. (2000) have confirmed that anionic liposomes were able to 
protect encapsulated oligonucleotides against in vitro and in vivo plasma nuclease 
degradation.  In addition, Chiou et al. (1994) have indicated that degradation of 
oligonucleotides bound to the asialoorosomucoid-poly-L-lysine conjugate, as determined 
via electrophoresis, radioactivity, and autoradiography, was inhibited approximately 3-6 
fold in fresh rat serum obtained from whole blood during 5 hours of incubation, 
compared with the uncomplexed oligonucleotide.  Recently, Ferreiro et al. (2003) have 
also demonstrated that complexation of oligonucleotides to polycationic carriers 
increased stability against intestinal nucleases in the gastrointestinal tract, possibly due 
to its forming a steric barrier to enzymes. 
 Chemical modification of oligonucleotide is considered as an alternative strategy 
to improve the nuclease resistance.  The end-capping and protection of internal 
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pyrimidine residues have been reported to improve nuclease stability (Peyman et al., 
1997).  Other investigators have synthesized the oligonucleotide with a self-forming 
hairpin to protect them from enzymatic degradation (Djavanbakht Samani et al., 2001).  
Recent work developed by Murata et al. (2003) has revealed that the 3´,5´-modified 
oligonucleotide-poly(N-isopropylacrylamide) conjugate was approximately 54% more 
resistant to S1 endonuclease than the unmodified oligonucleotide.  It is interesting to 
note that, in this work, PO-oligonucleotide was grafted into the polymer, suggesting that 
the stability of oligonucleotide was effectively improved by its polymer modification.  
Moreover, the grafted oligonucleotide was protected, possibly due to less accessibility of 
nucleases by steric hindrance of the polymer chain. 
 In conclusion, we were unable to kill leukemic T cells with the oligonucleotides 
used in our experiments.  Surprisingly, with an antibody dendrimer conjugate, toxicity of 
oligonucleotides was only marginally effective.  Thus, it becomes clear to us that the 
proper selection and/or design of an appropriate antisense sequence of target sites still 
remains a major challenge in the successful application of antisense technology.  
Computer-facilitated screening along with gene walking approaches are further required 
in order to identify accessible sites and to select effective antisense sequences.  
Therapeutic progress of antisense technology is closely related to the understanding of 
cellular delivery process.  Utilizing a size exclusion HPLC analysis, we were able to 
examine the portions of the oligonucleotide based on the difference in size and/or 
molecular mass that were degraded during incubation.  This work contributes to our 
better understanding of the degradation process associated with the intra- and 
extracellular environment, and further serves as an exploratory guide for rational design 
of a gene therapy vehicle. 
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CHAPTER IV 
DEVELOPMENT OF PAMAM DENDRIMER AS A POTENTIAL 
OLIGONUCLEOTIDE DELIVERY SYSTEM 
 
INTRODUCTION 
In order to enhance the efficacy and specificity of delivering exogenous materials 
into targeted cells, a well-defined delivery approach based on the use of potential 
carriers (vectors or transfection reagents) is needed.  Optimization of delivery vectors is 
one of the most important keys to the success of gene therapeutic applications (Varga et 
al., 2000; Ferber, 2001).  Typically, a delivery vector should provide efficient uptake and 
expression of the transgene to a selective cell type without stimulating a significant 
immune or cytotoxic response.  Several recently developed nonviral chemical-based 
carriers can form condensed complexes with DNA allowing for targeted delivery to 
specific cell types, increased delivery to the cytosol or nucleus, and dissociation in the 
cytosol or release in the tissue (Niidome and Huang, 2002).  Table 4.1 lists the 
transfection reagents and their effects.  Liposomes, mono- or multi-layered phospholipid 
vesicles, that are either anionic, neutral, fusogenic or cationic, are currently widely used 
in laboratory settings for transfection of mammalian cells.  Liposomes provide several 
advantages over conventional transfection methods such as calcium phosphate or 
electroporation, including enhanced delivery efficiency (Sasaki et al., 2001).  However, 
potential toxicity (Pardridge, 2002) and induction of specific immune response (Niidome 
and Huang, 2002) are still issues that need resolving.  In addition, relatively large size, 
high surface charge and their accumulation in the reticuloendothelial system limit their 
usefulness for in vivo cell transfection (Lou et al., 2001).  Cationic polymers have been 
extensively used for gene transfection of primary cells; however, their ability based upon 
transfection procedures most likely depends on the presence of effector agents (Cotten et 
al., 1990; Strauss, 1998).  Recent work developed by Lampela et al. (2004) has shown 
that the combination of cationic lipids and polyethylenimines result in increased 
transfection efficacy; however, these results are highly dependent upon reagent 
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Table 4.1.  Representative studies of transfection reagents in gene delivery in eukaryotic 
cells. 
 
Reagent Effects Investigators 
DEAE-dextran precipitation • High cytotoxicity • Vaheri and Pagano, 1965 
Calcium phosphate precipitation • High cytotoxicity • Graham and van der Eb, 
1973 
Electroporation/Permeabilization • High cell mortality 
• Relatively enhanced 
cellular uptake/Nuclear 
localization 
• Spiller et al., 1998 
Viral vectors • High efficiency 
• Potentially biological 
hazard 
(i.e. mutagenesis) 
 
Liposomes/Cationic lipids • Improved efficiency 
• Less cytotoxicity 
• Axel et al., 2000 
• Kronenwett et al., 1998 
Cationic polymers 
Dendrimers/Activated 
dendrimers 
 
• Protonability (i.e. 
buffering capacity) 
 
• High efficiency 
 
• Minimal cytotoxicity 
• Tang et al., 1996 
• Godbey et al., 1999a 
• Reviewed in Dennig and 
Duncan, 2002 
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chemistry and cell lines. 
The starburst dendrimer (from the Greek: dendron, tree; discovered in the late 
1970s), a.k.a. polyamidoamine (PAMAM) dendrimer, has received a great deal of 
attention as a novel nonviral vector with applications in drug delivery and gene therapy 
(Service, 1995; Cloninger, 2002; and others) (see Figure 4.1).  The dendrimers are 
highly branched three-dimensional macromolecules with defined size, shape, functional 
terminal surface, and relative physicochemical features comparable to globular proteins 
(Esfand and Tomalia, 2001).  Of particular interest in the functionality and/or molecular 
interactions, the functional terminal groups of dendrimers have been coupled with a 
variety of defined chemistries (Fréchet, 1994; Singh, 1998).  Dendrimers have been 
proven to increase gene transfer efficiency at the concentrations required for gene 
transfer without inducing immunogenicity (Eichman et al., 2000) and cytotoxicity 
(Haensler and Szoka, 1993; Bielinska et al., 1996).  They are shown to facilitate the 
uptake of oligonucleotides over oligonucleotides unassociated with polymer by 4-5 folds 
and maintain the functional capacity of associated oligonucleotides (Bielinska et al., 
1996).  Additionally, stable non-particulate oligonucleotide complexes of generation 5 
dendrimer at a high charge ratio in the presence of 30-70% serum have been shown to 
maintain a relative degree of oligonucleotide activity.  The use of a high concentration of 
serum in culture medium is important in in vivo gene therapeutic applications (Yoo et 
al., 1999). 
The importance of the interaction between dendrimer and DNA in successful 
gene or oligonucleotide delivery has previously been established (Haensler and Szoka, 
1993; Bielinska et al., 1996; Dennig, 2003; and others).  Dendrimers, which provide the 
ionic feature of interaction with DNA, induced efficient cellular uptake (Shah et al., 
2000).  Studies by Kukowska-Latallo et al. (1996) have demonstrated that dendrimers 
enhanced plasmid DNA transfection and expression in a variety of mammalian cell lines 
with minimal cytotoxicity. 
In this work, we examine properties of a series of PAMAM dendrimers that we 
believe are associated with success as an oligonucleotide delivery vehicle.  The 
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B 
 
NCH2CH2N[-(CH2CH2CONHCH2CH2N)-CH2CH2CONHCH2CH2NH2]4 
      generation 
NCH2CH2N[-(CH2CH2CONHCH2CH2N)-CH2CH2COOH]4 
----------------|-----------------------------------|---------------------------------------- 
initiator core  interior layer   terminal unit & group 
 
 
 
C 
 
Generation Calculated 
molecular 
weight (Da) 
Number of 
surface 
groups 
Number of 
internal 
positive 
groups 
Diameter (Å) 
(Tomalia et al., 
1990) 
2.0 3,256 16 12 29 
2.5 6,267 32 28 -- 
3.0 6,909 32 28 36 
3.5 12,931 64 60 -- 
4.0 14,215 64 60 45 
4.5 26,258 128 124 -- 
 
Figure 4.1.  Schematic representation of polyamidoamine (PAMAM) dendrimer.  (A) 
Structure and growth.  (B) Chemical structure.  (C) Calculated molecular weight, 
number of surface groups, number of internal positive groups, and diameter as a function 
of generation. 
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Generation 
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           0.0       1.0        2.0 (x = CONH(CH2)2NH2) 
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properties we studied include toxicity of the dendrimer delivery vehicle, the binding 
capacity of the vehicle, and affinity of the vehicle for oligonucleotides.  We describe a 
simple method to determine the binding of oligonucleotides to dendrimers and 
performed nonlinear regression, as well as parameter estimation to obtain relevant 
binding properties.  We measured the properties of the dendrimer vehicles, toxicity, 
binding capacity, and binding affinity, as a function of dendrimer generation.  These data 
enable us to begin to evaluate the interplay between different properties of the dendrimer 
delivery vehicle which will contribute to our ability to design a more effective delivery 
vehicle for oligonucleotides, siRNA, or genes. 
 
MATERIALS AND METHODS 
Materials  
Commercially available generation 2.0-4.5 PAMAM dendrimers were purchased 
from Aldrich (Milwaukee, WI) and used without further purification.  Cell culture 
reagents were purchased from GibcoBRL (Grand Island, NY).  5'-end-fluorescein 
isothiocyanate (FITC)-labeled oligonucleotide was purchased from Sigma-Genosys (The 
Woodlands, TX).  Aminolink and immobilized diaminodipropylamine (DADPA) gels 
were purchased from Pierce (Rockford, IL).  All other chemicals, unless otherwise 
specified, were obtained from Sigma (St. Louis, MO). 
 
Cell Culture  
Human T-cell leukemia TIB-152 Jurkat cells (ATCC, Rockville, MD) were 
cultured in a humidified 5% (v/v) CO2/air environment at 37°C in RPMI supplemented 
with 10% (v/v) FBS, 10 mM HEPES, 4.5 g/L glucose, 2 mM sodium pyruvate, 100 
U/mL penicillin, 100 µg/mL streptomycin, and 2.5 µg/mL amphotericin B (pH 7.4).  For 
the dendrimer toxicity experiments, cells were plated at densities ranging from 5 to 6 x 
105 cells/well in 96 well plates. 
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MTT Reduction Assay   
Jurkat cell viability was measured using the MTT reduction assay (Pollack et al., 
1995).  The dendrimers were incubated with the cells for various lengths of time, after 
which time MTT was added to the culture medium to yield a final MTT concentration of 
0.5 mg/mL.  Cells were incubated with the MTT for 4 hours in a CO2 incubator after 
which time 100 µL of a 5:2:3 N, N-dimethylformamide (DMF): sodium dodecyl sulfate 
(SDS): water solution (pH 4.7) was added to dissolve the formed formazan crystals.  
Then, after 20 hours of incubation in a humidified CO2 incubator, the MTT absorbance 
was measured using an Emax Microplate reader at 585 nm (Molecular Devices, 
Sunnyvale, CA).  Viability was reported relative to control cells unexposed to the 
dendrimers. 
 
FITC-Labeled Oligonucleotide Solution Preparation   
Stock solutions of 100 µM were prepared by dissolving the FITC-labeled 
oligonucleotides in TE (10 mM Tris, 1mM EDTA, pH 8.0).  The stock solutions were 
diluted in phosphate buffer saline (PBS, 13.67 mM NaCl, 2.68 mM KCl, 10 mM 
Na2HPO4, 1.76 mM KH2PO4, pH 7.2) to the concentrations used in the experiment. 
 
Equilibrium Binding Assay   
The H2N-terminated and HOOC-terminated dendrimers were coupled to 
aminolink and immobilized DADPA gels, respectively, according to the manufacturer’s 
instruction (see Appendix).  The FITC-labeled oligonucleotide at various concentrations 
was added to the dendrimer-linked gels, and the mixtures were then incubated at room 
temperature for either 30 minutes, 2 hours, or 3 hours.  After incubation, the suspensions 
were centrifuged at 5000 rpm for 2-5 minutes to separate free from bound 
oligonucleotides.  The fluorescence intensity (492 nm excitation and 520 nm emission) 
of the supernatant was measured to determine the concentration of free oligonucleotide 
using a Cary Eclipse fluorescence spectrophotometer (Varian Instruments, Walnut 
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Creek, CA).  Analogous experiments were performed using the quenched gels in all 
other ways. 
 
Estimation of Equilibrium Binding Constant of Oligonucleotides to Dendrimers   
Binding of oligonucleotides to dendrimers could be described by a functional 
form analogous to a Langmuir isotherm.  The following system of equations describe the 
binding in isolation at equilibrium (Equation 4.1) and the total binding as the simple sum 
of specific and nonspecific binding (Equation 4.2). 
0[ ][ ]
1 [ ]
S
C FB
F
K
=
+
        (4.1) 
[ ] [ ] [ ]T S NSB B B= +        (4.2) 
where BS termed specific binding represents the amount of oligonucleotide bound to the 
dendrimers, C0 represents the maximum binding capacity expressed in units of 
equivalent oligonucleotide concentration, F is the concentration of free oligonucleotide, 
K is an affinity equilibrium constant, BT denotes total binding, and BNS is the binding to 
the quenched gels referred to as nonspecific binding.  We then estimated parameters K 
and C0 from a non-linear least squares regression of the data corrected for nonspecific 
binding to the analytic solution of Equation 4.1 using SigmaPlot version 8.02 software 
(SPSS Inc., Chicago, IL). 
 
RESULTS 
Dendrimer Toxicity Experiments   
The toxicity of dendrimers was determined as a function of generation at 
different concentrations of dendrimer.  The data were reported as the fraction of the 
viability of the cells treated with the dendrimers for 24 and 48 hours relative to the 
viability of control cells unexposed to the dendrimers.  As seen in Figures 4.2A and 
4.2B, under all conditions, exposure to the H2N-terminated dendrimers resulted in cell 
toxicity.  While not shown, toxicity of H2N-terminated dendrimers increased with higher 
generation number.  Conversely, the HOOC-terminated dendrimers did not alter cell  
62 
  
A 
G3.5
G3.5 G3.5
G2.5
G2.0G2.0
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0 10 20 30 40 50
[Dendrimer] (µM)
Fr
ac
tio
n 
of
 V
ia
bi
lit
y 
 
B 
G3.5 G3.5 G3.5
G2.5
G2.0G2.0
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0 10 20 30 40 50
[Dendrimer] (µM)
Fr
ac
tio
n 
of
 V
ia
bi
lit
y
 
Figure 4.2.  Dendrimer toxicity experiment.  The toxicity of dendrimers was determined 
as a function of generation at different concentrations of dendrimer.  The data are 
reported as the fraction of the viability of the cells incubated with the dendrimers for (A) 
24 and (B) 48 hours relative to the viability of control cells unexposed to the dendrimers.  
The mean + standard deviation of 8-16 determinations are presented. 
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viability relative to untreated controls, regardless of generation number.  These results 
indicate that toxicity of dendrimers was dependent upon surface charge. 
 
Equilibrium Binding Assay   
   In order to estimate the equilibrium constant of the dendrimers for 
oligonucleotide delivery, we performed an equilibrium binding assay.  Preliminary 
experiments indicated that equilibrium binding was achieved in all cases within 2 hours.  
For all gels, both specific and nonspecific binding was estimated.  For an aminolink gel, 
the nonspecific binding of oligonucleotide to the gel was negligible, while for an 
immobilized DADPA gel, isotherms were corrected for nonspecific binding (see 
Appendix). 
   The oligonucleotide binding capacity, or maximum amount of oligonucleotide 
that the dendrimer vehicle could carry, increased with dendrimer generation for the 
amine terminated dendrimers; however, binding capacity did not appear to increase with 
size for the carboxylic acid terminated dendrimers (Figure 4.3 and Table 4.2).  For 
comparable size dendrimers, the amine terminated dendrimers had greater binding 
capacity than the carboxylic acid terminated dendrimers. 
   The binding capacity of the same dendrimer was also examined as a function of 
the ionic strength of the buffers.  Binding of oligonucleotides to dendrimers was greater 
at low salt than at physiological salt concentrations (Figure 4.4). 
 
Estimation of Equilibrium Binding Constant of Oligonucleotides to Dendrimers   
Figure 4.3 shows the best fits of our model equations to the experimental data.  
Using the nonlinear least squares regression of the data corrected for nonspecific binding 
to Equation 4.2, the values of two parameters, K and C0, were determined.  Table 4.2 
summarizes the model parameters for the binding of oligonucleotides to dendrimers at 
equilibrium.  While total binding capacities for dendrimers differed depending upon 
dendrimer size and surface group, equilibrium binding affinity was comparable for all 
dendrimers tested. 
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Figure 4.3.  Binding of FITC-labeled oligonucleotides to dendrimers.  Experiments were 
conducted at room temperature in phosphate buffer saline (PBS, 13.67 mM NaCl, 2.68 
mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4) at pH 7.2.  Equilibrium binding of the 
FITC-labeled oligonucleotide to dendrimers is plotted as mmole·(mmole dendrimer)-1 
versus concentration.  (A) Generation 2.0.  (B) Generation 3.0.  (C) Generation 4.0.  (D) 
Generation 3.5.  (E) Generation 4.5.  The lines represent the best fit of Equation 4.1 to 
the data. 
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Figure 4.3.  (Continued) 
 
 
 
 
 
 
 
 
66 
  
E 
[Free Oligonucleotide] (nM)
0 20 40 60 80 100
Bo
un
d 
O
lig
on
uc
le
ot
id
e 
(m
m
ol
e/
m
m
ol
e 
de
nd
rim
er
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
 
 
Figure 4.3.  (Continued) 
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Table 4.2.  Summary of model parameters obtained in equilibrium binding experiments. 
 
Generation   K            C0 
    M-1            mmole·(mmole dendrimer)-1 
2.0    2.1 ± 0.8·107           0.009 ± 0.002 
 
3.0    1.2 ± 0.1·107           0.46 ± 0.02 
 
3.5    1.3 ± 0.3·107           0.51 ± 0.08 
 
4.0    8.4 ± 0.9·106           1.24 ± 0.05 
 
4.5    3.0 ± 0.9·107           0.37 ± 0.05 
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Figure 4.4.  Effect of salt on binding of FITC-labeled oligonucleotides to generation 3.0 
dendrimer.  Experiments were conducted at room temperature in phosphate buffer saline 
(PBS, 13.67 mM NaCl, 2.68 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4) at pH 7.2 
and phosphate buffer (10 mM Na2HPO4, 1.76 mM KH2PO4) at pH 7.2, respectively.  
Equilibrium binding of the FITC-labeled oligonucleotide to dendrimers is plotted as 
mmole·(mmole dendrimer)-1 versus concentration.  (A) Phosphate buffer saline (0.13 M 
ionic strength).  (B) Phosphate buffer (0.01 M ionic strength).  The lines represent the 
best fit of Equation 4.1 to the data. 
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DISCUSSION 
One strategy for developing a gene or oligonucleotide delivery vehicle is to 
develop a vehicle that changes the physical properties of the oligonucleotide or gene 
such that its delivery to the target cell (and location of choice within the cell) is 
facilitated.  Numerous barriers must be overcome to achieve biological activity of the 
delivered oligonucleotide (inhibition of protein expression for antisense or siRNA) into 
targeted cells.  Formation of a complex between the delivered oligonucleotide and a 
carrier is considered as one of the important steps for nonviral gene delivery.  PAMAM 
dendrimers which possess primary amine or carboxylate groups on the surface and 
tertiary amines in the interior, as potential carriers, interact electrostatically with the 
nucleotide phosphates on oligonucleotides at physiological pH to form a compact 
particle and neutralize its charge. 
The biological properties of dendrimers, especially their toxicity and 
immunogenicity, are considered to be of critical importance for their use in biological 
applications.  Studies by Roberts and coworkers have indicated that in vitro toxicity of 
dendrimers appears to be concentration and generation dependent.  In this study, V79 
fibroblast cells were exposed to generation 3.0, 5.0 and 7.0 dendrimers at a concentration 
of 0.1-1000 µM for 4 and 24 hours.  Lower generations affected cell growth only at high 
concentrations, whereas the generation 7.0 dendrimer caused cell death at all the 
concentrations tested.  Moreover, no evidence of immunogenicity of any dendrimer 
generation tested was observed (Roberts et al., 1996).  Malik et al. (2000) examined the 
structure-biocompatibility relationship, and suggested that PAMAM dendrimers bearing 
the amine surface above a concentration of 1 mg/mL as assessed via MTT reduction and 
haemolysis assays were toxic and induced haemolysis after 72 hours and 1 hour 
exposure, respectively.  However, the carboxylate terminated derivatives were less toxic 
up to a concentration of 2 mg/mL.  In vivo bio-distribution studies have shown that, 
owing to inherent toxicity, higher generation cationic dendrimers would unlikely be 
suitable for parenteral administration.  In our toxicity experiment, as seen in Figures 
4.2A and 4.2B, we found that exposure to the amine terminated dendrimers resulted in 
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cell toxicity, in accord with the above findings.  We suggest that it is likely due to their 
highly polycationic nature.  The positively charged dendrimers likely interact directly 
with the negatively charged cell membrane, causing disruption of essential membrane 
properties associated with cell survival. 
Several investigators have previously attempted to characterize physical stability 
and the particle size of the oligonucleotide complexes (Tang and Szoka, 1997; Ferreiro 
et al., 2001).  In one study, the biophysical properties of the interaction between different 
cationic polymer structures and DNA were examined using electron microscopy and 
dynamic light scattering.  The apparent diameter and extent of aggregation of the 
compact structures in solution, referred to as toroidal complexes of 40-60 nm in 
diameter, strongly depend upon the characteristics of the individual cationic polymer and 
its charge ratio.  More importantly, the apparent binding of cationic polymers to DNA is 
a linear function of solution ionic strength, which has proven that the interaction 
between cationic polymers and DNA is predominately electrostatic (Tang and Szoka, 
1997).  Another study by Ferreiro et al. (2001) has shown that stability of 
oligonucleotides with poly-L-lysine and protamine salts is pH dependent as determined 
via the zeta potential analysis.  Moreover, an increase in the ionic strength likely 
promoted dissociation of the complexes.  The DNA dissociation characteristics of the 
polymer complex once present in the cytosol and/or nucleus is essential from the 
therapeutic point of view (Arigita et al., 1999).   
In this study, we examined binding properties of oligonucleotides to a series of 
dendrimers from generations 2.0-4.5 and estimated the equilibrium binding capacities 
and association constants for the binding at equilibrium.  Our assay technique is accurate 
and simple and is, therefore, important in studying binding interaction.  As seen in 
Figure 4.3 and Table 4.2, binding capacity of oligonucleotides to dendrimers is a strong 
function of generation number.  Protonation of primary amines and higher order amines 
at neutral pH could account for the binding of negatively charged oligonucleotides to the 
highly branched polymers (Tang and Szoka, 1997).  For amine terminated dendrimers, 
the number of positive charges on the dendrimer roughly doubles with every generation.  
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While binding capacity roughly doubles between generation 3.0 and 4.0 dendrimers, in 
accord with the increase in charge, there is a much more dramatic increase in binding 
between generation 2.0 and 3.0.  Possibly, generation 3.0 and 4.0 dendrimers have a 
relatively open and flexible structure compared to generation 2.0, which allows 
oligonucleotides to enter and reside in the large charged interior, thus facilitating its 
binding of oligonucleotides.  For the carboxylic acid terminated dendrimers, the same 
increase in binding capacity with size and increased number of internal positive charges 
was not observed, possibly because the surface charges contribute to binding capacity 
much more significantly than the internal charges on the polymer. 
As shown in Figure 4.4, binding affinity of oligonucleotides to dendrimers is 
influenced by the salt concentration.  Various research groups have previously 
demonstrated the electrostatic nature of the interaction of the DNA and polycations 
(Pelta et al., 1996; Bielinska et al., 1999; Plank et al., 1999).  Precipitation of DNA and 
resolubilization of its aggregates induced by subsequent addition of polyamines is a fully 
reversible process.  Interestingly, precipitation appears to be dependent on DNA 
concentration between 1-50 µg/mL (Pelta et al., 1996).  Bielinska et al. (1999) have 
fractionated aggregated dendrimer-DNA complex and then characterized 
physiochemical properties involved with the formation of this non-uniform complex.  In 
particular, formation of high-density and less soluble complexes was associated with the 
complex charge ratio and high DNA concentrations ranging from 0.04 to 1 µg/µL.  
Electrostatic charge related effects of charged particles appear to be modulated by the 
generation (i.e. size) of dendrimers.  Based on their work, it is likely that dendrimers 
form neutralized complexes with DNA in a stoichiometry that in primary amines to 
DNA phosphates is equal to one. 
Plank et al. (1999) have synthesized and characterized binding and compacting 
characteristics of a series of branched cationic peptides that differ in the number and 
type of cationic amino acids.  Peptide affinity for DNA increased with the number of 
cationic groups in the polypeptide, and a minimal chain length of six to eight cationic 
amino acids was necessary for the formation of DNA complexes.  The peptide 
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compacted DNA into a microparticulate structure, and its compacting potency has been 
shown to be structure dependent as determined via an ethidium bromide displacement 
assay, dynamic light scattering, and electron microscopy.  The estimated association 
constants of branched peptides based on a competitive binding assay were found to be in 
the range of 106 M-1 to 109 M-1.  These equilibrium association constants are of the same 
order of magnitude that we found for the PAMAM dendrimers tested in this work.  We 
found; however, that equilibrium association constant did not change with dendrimer 
charge (and that only maximum binding capacity was a function of charge).  We 
speculate, in our work, that the association constant (or binding affinity) is a function of 
type of polycation (primary or tertiary amine), while binding capacity is a function of 
total charge of the dendrimer. 
In summary, we examined the dendrimer toxicity, binding capacity, and binding 
affinity with oligonucleotides under physiological and low ionic strength conditions.  
We presented a simple novel dendrimer-linked gel-based method to obtain equilibrium 
isotherms and estimated the binding constants for dendrimers.  Previous studies have 
developed the nitrocellulose-filter binding to determine protein-nucleic acid interactions 
(Wong and Lohman, 1993).  Formation of a complex between the delivered gene and a 
carrier is considered as one of the important steps for nonviral gene delivery.  The 
binding affinity between carrier and gene or oligonucleotide has been implicated in the 
stability of the complex toward dissociation in an intra- and extracellular environment.  
These results may help to design better therapeutic vectors for gene or oligonucleotide 
delivery. 
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CHAPTER V 
KINETIC ANALYSIS OF AN ANTIBODY DENDRIMER 
CONJUGATE FOR OLIGONUCLEOTIDE DELIVERY 
 
INTRODUCTION 
Several investigators have proposed a conceptual cellular delivery system in 
which uptake of oligonucleotide is driven through an energy-dependent mechanism.  
Endocytosis (receptor-mediated, adsorptive and fluid-phase or pinocytosis) and non-
endocytosis associated with specific proteins are believed to be involved in the cell 
membrane transport and cellular internalization of oligonucleotides (Cotten et al., 1990; 
Gewirtz et al., 1996; Wu-Pong et al., 1997; Garcia-Chaumont et al., 2000; Lou et al., 
2001; and others).  Upon internalization, endosomal compartments undergo continuous 
acidification from the initial cell surface pH (~7) to that found in lysosomes (~4) through 
the action of ATP-dependent proton pumps acting in conjunction with other ion 
transporters found in the membrane.  Endocytosed oligonucleotides then escape the 
endosomal and lysosomal compartments and bind to their mRNA targets for 
transcription (Phillips and Gyurko, 1997; Varga et al., 2000).  Studies by Yakubov et al. 
(1989) have shown that an endocytosis mechanism is found to be concentration 
dependent. 
A number of investigators have used antibodies to target oligonucleotides to 
specific cell surface receptors on diseased cells.  Once bound to the cell surface receptor, 
receptor mediated endocytosis leads to internalization of the oligonucleotide in the 
specific cell population.  Suh et al. (2001) have targeted thiolated poly-L-lysine to a 
PDPH-modified antibody reactive against the human T cell leukemia-specific JL-1 
antigen for delivery of oligonucleotides to leukemia cells.  Based on their work, 0.54 x 
104 of JL-1 antigen are found to be present within the cell.  They showed that an 
antibody complex was effectively internalized into cells, possibly via receptor-mediated 
endocytosis.  In other studies, the polyethylenimine (PEI) anti-CD3 antibody conjugate 
was shown to promote nuclear localization of oligonucleotide in human lymphoma cell 
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lines through an endocytic pathway (Guillem et al., 2002).  Similar strategies have 
worked in other cancerous cells, as exemplified by work from Patri et al. (2004) that 
showed that the anti-prostate specific membrane antigen (PSMA) antibody dendrimer 
conjugates targeting prostate cancer bind to cells expressing PSMA.  Other targeting 
proteins outside of antibodies can also lead to internalization of oligonucleotides.  For 
example, recent work developed by Hussain et al. (2004) has revealed that trypsin-
sensitive surface binding proteins may be involved in energy-dependent mechanism of 
cellular uptake. 
Facilitation of endosomal sorting escape before lysosomal degradation has been 
pharmacologically proposed to improve the efficacy of oligonucleotide delivery (Lou et 
al., 2001).  In a very elegant study, Mikos and coworkers (Godbey et al., 1999b) have 
revealed details about endocytotic trafficking of the PEI complex using fluorescent 
labeling and confocal microscopy.  The labeled complex initially attached to the cell 
surface, formed an aggregate (or patch) which was then endocytosed, and entered the 
nuclei as an associated complex.  Upon nuclear localization, the phospholipid-coated 
complex either interacted with the nuclear membrane or permeabilized and fused with 
the nuclear envelope, thus leading to the release of a complex into the nucleus.  The 
ability to protonate PEI makes it an effective buffer within endo-lysosomes, and may 
facilitate its efficient delivery into the nucleus. 
Various research groups have hypothesized potential molecular mechanisms of 
oligonucleotide uptake by cells when receptor mediated endocytosis and/or antibody 
targeting is not involved, but instead polycations are used to deliver oligonucleotides to 
cells.  A zipper-like association between the positively charged polycation complex and 
negative charges on the cell surface resulting in adsorptive endocytosis and membrane 
destabilization has been proposed as a predominant role in the process of internalization.  
The effectiveness of dendrimer-mediated transfection is altered relative to complex 
charge ratio, diameter of the dendrimer, and binding of membrane-destabilizing 
peptides.  In addition, transfection efficiency has been shown to be related to the pKa of 
the amines in the polymer which probably allow the dendrimer to buffer the pH change 
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in the endosomal compartment (Haensler and Szoka, 1993).  Further studies have found 
that the dendrimer complex enhances oligonucleotide stability under buffer or ionic 
strength variation due to charge-based association and increased nuclear delivery 
(Kukowska-Latallo et al., 1996; Delong et al., 1997).  In these studies, based on cell 
type, dendrimer surface charge has proven to be important in the mechanism of 
transfection. 
In the present study, we use an antibody to the IL-2R to target the dendrimer-
oligonucleotide complex to a T cell leukemia (Jurkat) cell line.  The use of the IL-2R as 
a selective marker for more conventional chemotherapeutic agents has been addressed 
many times in the past (Sobolev et al., 2000).  Frankel and coworkers (1995) synthesized 
a genetically altered IL-2-ricin conjugate to target HUT102 human leukemia T cells 
bearing the high affinity IL-2 receptor; Linares (2000) used IL-2 to deliver 
photosensitizers to Jurkat (TIB-152) leukemia T cells expressing the IL-2R α chain; and 
Foss (2001) tested IL-2 genetically fused to the enzymatically active and translocating 
domains of diphtheria toxin also using high affinity IL-2 receptor bearing cells.  In 
addition, anti-CD25 immunotoxins (Amrolia et al., 2003; Michalek et al., 2003) have 
been examined to selectively deplete activated T cells associated with graft versus host 
disease.  The IL-2R is a relatively low abundance receptor (less than 2000 copies per cell 
in many cancers); however, its attractiveness as a target is in its rapid rate of 
internalization.  In vitro studies suggest that internalization of the IL-2 receptors occurs 
continuously (Duprez and Dautry-Varsat, 1986).  The initial rate of internalization of 
ligands associated with its high-affinity sites is on the order of 10-1 min-1 (Weissman et 
al., 1986; Lowenthal et al., 1986). 
Here, we measured kinetic and thermodynamic parameters associated with 
binding and internalization of anti-IL-2R antibody-dendrimer-oligonucleotide complexes 
that were developed for delivery of oligonucleotides to a model T cell leukemia (Jurkat) 
cell line that constitutively expresses the IL-2 receptor.  We experimentally determined 
the dependence of binding and internalization on dendrimer size and surface charge.  
The ability to characterize the effects of different delivery vehicle properties on 
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oligonucleotide delivery may facilitate the design of a more effective treatment strategy 
for antisense, siRNA, or gene delivery to IL-2R bearing cells. 
 
MATERIALS AND METHODS 
Materials   
   Commercially available generation 2.0-4.0 PAMAM dendrimers were purchased 
from Aldrich (Milwaukee, WI) and used without further purification.  Cell culture 
reagents were purchased from GibcoBRL (Grand Island, NY).  Alexa fluor 532 protein 
labeling kit was purchased from Molecular Probes (Eugene, OR).  1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) was purchased from Pierce 
(Rockford, IL).  All other chemicals, unless otherwise specified, were obtained from 
Sigma (St. Louis, MO). 
 
Cell Culture   
   Mouse HB-8555 hybridoma cells (ATCC, Rockville, MD) were cultured in a 
humidified 5% (v/v) CO2/air environment at 37°C in RPMI supplemented with 10% 
(v/v) FBS, 2 mM L-glutamine, 10 mM HEPES, 4.5 g/L glucose, 1 mM sodium pyruvate, 
0.025 mM 2-mercaptoethanol, 100 U/mL penicillin, 100 µg/mL streptomycin, and 2.5 
µg/mL amphotericin B (pH 7.4).  Culture supernatant was collected every 4 to 5 days 
and stored at 4°C for further antibody purification.  Human T-cell leukemia TIB-152 
Jurkat cells (ATCC, Rockville, MD) were cultured in a humidified 5% (v/v) CO2/air 
environment at 37°C in RPMI supplemented with 10% (v/v) FBS, 10 mM HEPES, 4.5 
g/L glucose, 2 mM sodium pyruvate, 100 U/mL penicillin, 100 µg/mL streptomycin, and 
2.5 µg/mL amphotericin B (pH 7.4).  Cells were plated at densities ranging from 4 to 5 x 
105 cells/mL in 96 well plates for binding and internalization experiments. 
 
IL-2 Receptor Monoclonal Antibody Purification   
   Anti IL-2R (CD25) monoclonal antibody was purified from cell culture 
supernatant by affinity chromatography using a protein A Sepharose 4 Fast Flow column 
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(Pharmacia, Piscataway, NJ) via standard techniques (Harlow and Lane, 1988; Montage 
Antibody Purification Kit and Spin Columns with PROSEP-A Media User Guide, 
Millipore, Bedford, MA).  The culture supernatant from HB-8555 cells was filtered 
through a 0.22-0.45 µm pore size, 47 mm diameter filter (Millipore, Bedford, MA) and 
diluted 1:1 (v/v) in binding buffer (1.5 M glycine/NaOH, 3 M NaCl, pH 9.0) before 
loading.  The column was washed with 10 bed volumes of binding buffer to remove 
unbound contaminants.  The bound antibody was then eluted with elution buffer (0.1 M 
sodium citrate, pH 5.5). 
   The pH of purified antibody was neutralized using 1:20 (v/v) neutralization 
buffer (1M Tris/HCl, pH 9.0).  The antibody solution was concentrated using the 
Microcon ultra centrifugal filter device with a 30000 molecular weight cut off membrane 
(Millipore, Bedford, MA).  The concentration and purity of antibody were then 
determined by the absorbance reading at 280 nm (1 OD is approximately equal to 0.8 
mg/mL) and SDS PAGE using the pHastgel system (Pharmacia, Piscataway, NJ), 
respectively.  An antibody was stored at -20°C until use. 
 
Alexa Fluor 532 Antibody Labeling   
An antibody at a concentration of 0.4 mg/mL in 0.1 M sodium bicarbonate pH 
8.3 was added to the alexa fluor 532 (pH insensitive) reactive dye.  The mixture was 
allowed to react for 2 hours at room temperature, followed by purification using a 15000 
molecular weight cut off resin column in phosphate buffer saline (PBS, 150 mM NaCl, 
10 mM KH2PO4/K2HPO4, 0.2 mM sodium azide, pH 7.2).  A fraction containing 
antibody was collected and measured with the absorbance readings at 280 nm and 530 
nm to determine the degree of labeling.  The approximate fluorophore to antibody ratios 
were calculated based on the extinction coefficient of alexa fluor 532 and on the average 
molecular mass of the antibody. 
 
Antibody Dendrimer Conjugation   
Solutions of dendrimer and EDC were mixed in conjugation buffer (0.1 M MES, 
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pH 5.0) in a molar ratio of 1:1.  The alexa fluor 532-conjugated antibody was added to 
the complex mixture and rotated at 60 revolutions per minute at room temperature for 3 
hours.  An antibody dendrimer conjugate was then purified on a PD-10 desalting column 
(Pharmacia, Piscataway, NJ) in phosphate buffer saline (PBS, 13.67 mM NaCl, 2.68 mM 
KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.2) and the first peak containing 
antibody was collected.  Unreacted reagents were further removed via ultra filtration 
through a 30000 molecular weight cut off membrane (Millipore, Bedford, MA).  The 
protein content was then measured with the absorbance readings at 280 nm and 530 nm 
to calculate the degree of conjugation. 
 
Cellular Binding and Internalization Assays   
   The interaction of antibody dendrimer conjugates with cells was evaluated using 
flow cytometry of the fluorescent labeled antibody-dendrimer complex.  The alexa fluor 
532-conjugated antibody was titrated to estimate the optimal concentration for our 
procedure used to process the cells (Loken et al., 2000).  The amount of antibody was 
determined and held constant at 10.2 nM. 
   Human T-cell leukemia TIB-152 Jurkat cells at densities ranging from 4 to 5 x 
105 cells/mL were incubated in 200 µL of RPMI at 4°C and 37°C for the indicated times 
with an antibody dendrimer conjugate.  Each cell sample was then analyzed by flow 
cytometry to determine the fluorescence level.  The data presented here thus show the 
amount of total cell associated antibody dendrimer complex, both bound and 
internalized. 
   Flow cytometry was performed with a FACSArray bioanalyzer (Becton 
Dickinson, San Jose, CA) equipped with a green (532 nm) laser to excite alexa fluor 532 
(530 nm excitation).  The emission of alexa fluor 532 (554 nm) was filtered using a 
yellow 564-606 nm band pass filter.  Typically, 5000-10000 events per sample were 
collected.  The mean fluorescence of the whole cell after subtraction of background 
fluorescence was reported to represent the degree of delivery. 
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Model and Parameter Estimation   
   We assumed that our experimental system could be described by the steady state 
process and characterized by first order rate constants.  Figure 5.1 illustrates the 
schematic description of the endocytic process.  The following system of equations 
described the mass action kinetics of conjugate binding to cell receptor (Equation 5.1) 
and internalization (Equation 5.2). 
f
r
k
s sk
Ab D R Ab D R− + − −ZZZXYZZ      (5.1) 
ik
s iAb D R Ab D R− − → − −      (5.2) 
where Ab-D represents the concentration of the unbound conjugate, Rs represents the 
number of cell surface receptors, Ab-D-Rs and Ab-D-Ri are the concentrations of the 
bound and internalized conjugates, respectively, kf is an association rate constant, kr is a 
dissociation rate constant, and ki is an internalization rate constant. 
            In order to estimate ki, we used data obtained from experiments performed at 4°C 
and 37°C, and the fluorescence associated with the cells was compared, correcting for 
the change in both rate of binding and equilibrium binding at the two temperatures.  We 
then estimated the parameter ki from a linear least squares regression of the data to the 
analytic solution of Equation 5.2. 
 
Estimation of Standard Enthalpy Change of Dendrimer Conjugates  
   The standard enthalpy change of dendrimer conjugates for the reversible 
reaction, ∆H°, can be described by the Van't Hoff relation (Equation 5.3). 
2
lnd K H
dT RT
°∆=         (5.3) 
Equation 5.3 can be integrated on the assumption that ∆H° is constant over the 
temperature interval.  Thus, the result is: 
1
2 2 1
1 1ln K H
K R T T
°  ∆= −  
      (5.4) 
where K is the equilibrium constant, R is the universal gas constant (= 1.987 cal/K 
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Figure 5.1.  Schematic description of the endocytic process.  The ligand molecules 
(circles) bind to the target receptors (block arcs).  Receptors and their ligands are 
internalized into the cell (shaded area represents the plasma membrane).  
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mole), and T is the absolute temperature in Kelvin.  Note that ∆H° < 0, K decreases with 
increasing T, for an exothermic and conversely for an endothermic reaction. 
The equilibrium constant can be expressed as: 
 
   
   [ ]
[ ][ ] [ ][ ]
corrected
s
s s
Average of Mean Fluorescence
Fluorophore to Antibody RatioAb D RK
Ab D R Ab D R
  − −  = − −  (5.5) 
where the concentration of the bound conjugate in Equation 5.5 is defined by the ratio of 
average of the mean fluorescence after subtraction of background fluorescence to the 
approximate moles of fluorophore per mole of antibody.  The number of cell surface 
receptors is assumed to be constant.  The concentration of the unbound conjugate is 
constant throughout the experiment.  This assumption was based on our procedure that 
conjugate was used in excess concentrations. 
 From binding and internalization data at 4°C and 37°C, we estimated apparent 
equilibrium binding affinities for each of the antibody dendrimer conjugates at the two 
temperatures (Equation 5.5).  From the binding constants we then estimated the standard 
enthalpy change with binding of the data to the analytic solution of Equation 5.4. 
 
RESULTS 
Conjugate Characterization   
   Several different antibody dendrimer conjugates were prepared using three 
different H2N-terminated dendrimers.  After preparation and purification, the amount of 
bound dendrimer to antibody of each conjugate was characterized.  The degree of 
conjugation was determined by the absorbance readings at 280 nm and 530 nm.  On the 
basis of this measurement, it was calculated that the molar ratio of greater than 1000 
dendrimer to antibody for conjugates after purification.  We believe that the high 
conjugation ratio reported here is a result of our failure to completely remove 
unconjugated dendrimer from the conjugated antibody. 
 
Cellular Binding and Internalization   
   In order to estimate the binding and internalization rate constants of the antibody 
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dendrimer conjugate used for oligonucleotide delivery to a T cell leukemia line (Jurkat 
cells), we conducted a fluorescence-based flow cytometry assay.  The binding and 
internalization of antibody dendrimer conjugates prepared with different dendrimer size 
generations was monitored as a function of time (Figure 5.2 and Figure 5.3).  The data 
were reported as the amount of conjugates bound or internalized per cell.  The quantity 
of conjugate associated with cell was estimated based on fluorescence measurements and 
calibration beads specific for the fluorophores used in these experiments.  In the binding 
experiments shown in Figure 5.2, in the absence of oligonucleotide, significantly more 
conjugate prepared with generation 2.0 dendrimer binds to cells than generation 3.0 or 
4.0 dendrimer.  However, the rate of binding of generation 2.0 dendrimer is slower than 
the rate of binding of the other conjugates.  The data shown in Figure 5.2 was collected 
at 4°C, a temperature at which receptor mediated endocytosis does not occur. 
   To determine conjugate internalization, experiments were performed at 4°C and 
37°C, and the fluorescence associated with the cells was compared, correcting for the 
change in both rate of binding and equilibrium binding at the two temperatures.  We 
assumed binding was rapid at 37°C and that internalization was first order.  As can be 
seen in Figure 5.3, internalization for all dendrimer conjugates is low; however the rate 
of internalization is highest for generation 2.0, then generation 3.0 dendrimer conjugates 
relative to generation 4.0 dendrimer conjugates, 0.05, 0.04 and 0.02 hr-1 respectively, or 
approximately 70, 20 and 10 conjugates per hour, respectively, for the three conjugates. 
 
Estimation of Standard Enthalpy Change  
   From binding and internalization data at 4°C and 37°C, we estimated apparent 
equilibrium binding affinities for each of the antibody dendrimer conjugates at the two 
temperatures.  From the binding constants we estimated the standard enthalpy change 
with binding as a function of antibody dendrimer conjugates.  As shown in Figure 5.4, 
all conjugates have lower change in enthalpy upon binding to the receptor than the 
unmodified antibody; however, the generation 4.0 conjugates show the greatest change 
in enthalpy from the unmodified antibody, suggesting the greatest loss in specificity of 
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Figure 5.2.  Time course of conjugate binding to cells as a function of antibody 
dendrimer conjugates.  Cells were treated with the antibody dendrimer conjugate at 4°C 
for varying periods of time.  The mean ± standard error from 3 to 7 replicates are shown.  
The amount of conjugates bound per cell is plotted for antibody dendrimer conjugate for 
dendrimers of generation 2.0 (-■-), 3.0 (-●-), and 4.0 (-♦-).
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Figure 5.3.  Time course of conjugate binding and internalization to cells as a function 
of antibody dendrimer conjugates.  Cells were treated with the antibody dendrimer 
conjugate at 4°C and 37°C for varying periods of time.  The mean ± standard error from 
3 to 7 replicates are shown.  The amount of conjugates bound (-●-) or internalized (-●-) 
per cell is plotted for antibody dendrimer conjugate with dendrimers of (A) generation 
2.0, (B) generation 3.0, and (C) generation 4.0. 
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Figure 5.3.  (Continued) 
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Figure 5.4.  Standard enthalpy change as a function of antibody dendrimer conjugates.  
The standard enthalpy change for the temperature dependence of the equilibrium 
constant for the antibody dendrimer conjugate for dendrimers of generation 2.0, 3.0 and 
4.0 are shown, and are compared with unmodified antibody. 
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binding of the three types of conjugates prepared. 
 
DISCUSSION 
Normal resting T cells do not express the IL-2R α, whereas T cells found in 
certain lymphoid malignancies and some autoimmune diseases over-express this 
receptor.  This provides the basis to targeted T cell therapies specifically.  In this work 
we examined the kinetic parameters that control effective uptake and intracellular 
trafficking of an antibody dendrimer conjugate to the IL-2R bearing T cells as part of the 
proposed therapy.  This targeted delivery vehicle could be used to deliver genes, 
antisense DNA or small interfering RNA to specific diseased cells. 
While there have been numerous studies of antibody mediated targeting and 
delivery of more traditional chemotherapeutics (Blakey et al., 1988), factors that govern 
effective internalization and delivery of non-charged or protein therapeutics may not 
apply to highly charged carriers for oligonucleotides.  For traditional immunotoxin 
delivery, internalization and intracellular degradation of the immunotoxin govern (and 
severely limit) the effectiveness of therapy (Press et al., 1988; Braslawsky et al., 1991; 
May et al., 1991; Yazdi et al., 1995).  However, for delivery of antisense 
oligonucleotides using cationic polymers or peptides, the high charge of the carriers may 
facilitate internalization and escape of the oligonucleotides from endosomes. 
We examined the binding affinity, enthalpy of binding, and rate of internalization 
of a number of antibody dendrimer conjugates.  In all cases, enthalpy of binding was 
significantly less than unmodified antibody, probably due to electrostatic interactions 
associated with the dendrimer.  Generation 4.0 dendrimer construct behaved least like 
the unmodified antibody, suggesting that the greater surface charges associated with the 
molecule were associated with the change in properties relative to the unmodified 
antibody.  Steric factors may have also played a role in the change in properties 
associated with dendrimer conjugation.  It might be possible that some free dendrimer is 
absorbed in the conjugate, and that not all dendrimer is covalently linked to the 
conjugate.  The reduction in enthalpy of binding of antibody dendrimer conjugate could 
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lead to loss of specificity of the antibody for a specific cell surface receptor. 
The rate of internalization of dendrimer conjugates was estimated.  In all cases, 
internalization was significantly slower, by more than a factor of 100, than that expected 
for IL-2 bond to its receptor (Weissman et al., 1986; Lowenthal et al., 1986).  The larger 
size dendrimer-antibody conjugates (generation 4.0) were internalized more slowly than 
the smaller dendrimer-conjugates (generation 2.0).  The reduced rate of internalization 
may be associated with either charge or molecular size.  Numerous lines of evidence 
have shown that cationic dendrimers interact electrostatically with oligonucleotide 
forming complexes that are efficiently internalized by endocytosis.  The size, structure 
and overall charge of complexes are critical for efficient delivery from the therapeutic 
point of view (Maksimenko et al., 2003).  Studies by Tomlinson and Rolland (1996) 
confirm this hypothesis.  The transfection efficiency of the dendrimer complex 
significantly increased as a function of polymer to DNA charge ratio as assessed via β-
galactosidase activity.  Additionally, Kronenwett and coworkers (1998) showed the 
enhanced cationic lipid-mediated oligonucleotide uptake in primary hematopoietic cells, 
which appeared to be cell type dependent with the smallest uptake in CD7+ T cells. 
Several investigators have previously elucidated the structure/function 
relationships of the delivery vectors for gene transfer (Tang et al., 1996; Akinc et al., 
2003; Anderson et al., 2004; and others).  In one study, the fractured (i.e. partially 
degraded) PAMAM dendrimer obtained from random solvolysis aided by heat leading to 
hydrolytic cleavage of some peptide bonds increased transfection efficiency, mainly due 
to its high degree of flexibility.  Indeed, this highly flexible structure acting as a proton 
sponge, which becomes protonated, swelled and eventually bursted upon uptake in the 
endosome, would cause endosomal rupture and release of free DNA or the complex into 
the cytoplasm.  Moreover, the protonation of dendrimer would buffer the acidic 
environment of the endosome, which may inhibit pH-dependent endosomal nucleases 
(Tang et al., 1996).  Audouy and Hoekstra (2001) reviewed that the size of cationic lipid 
complexes may play an important role in transfection mechanism, likely due to the 
restricted diameters of endocytic vehicles (~100 nm) and time-dependent clustering of 
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complexes prior to internalization.  In addition, Langer and his teams suggested that 
small particle sizes and positive surface charges of newly synthesized degradable poly 
(β-amino esters) led to higher levels of cellular uptake (Akinc et al., 2003).  
Furthermore, they demonstrated both in vitro and in vivo use of C32 polymer-based 
vector, synthesized at 1.2:1 amine per acrylate ratio, to selectively and effectively deliver 
a DNA construct encoding the A chain of diphtheria toxin to human prostate cancer cells 
without its associated cytotoxicity.  The amino termination has been shown to improve 
transfection, in this case, suggesting that the extra positive charge may assist DNA 
complexation or some step in the transfection process (Anderson et al., 2004). 
Since efficient delivery of the biotherapeutic agent appears to be linked to 
endosomal release and sorting, engineering a vector to overcome this limiting barrier can 
facilitate its escape.  Lackey et al. (2002) investigated the use of pH-sensitive 
poly(propylacrylic acid) as an endosomal-releasing agent to enhance the cytoplasmic 
translocation of anti-CD3 antibody conjugates across the endosomal membrane in T 
lymphoma cells. 
The overall positive charge of an antibody dendrimer conjugate has been shown 
to mediate electrostatic interactions with the negatively charged glycosides present on 
the cell surface.  The positively charged complex may increase binding of the negative 
charge of the cell surface nonspecifically, thereby reducing the efficiency and specificity 
of a targeted complex.  In this regard, it is important to note that the dendrimer may be 
internalized via fusion or membrane destabilization upon its interaction with the cell 
surface.  Recently, Hong et al. (2004) proposed that the formation of holes, of 
approximately 15-40 nm, (i.e. dendroporation) generated in the cell membrane by amine 
terminated dendrimers is responsible for nonselective internalization.  Others showed 
that, using an endothelial cell line as a model, membrane cholesterol and raft (i.e. 
probably the annular anionic phospholipids surrounding raft) integrity are relevant for 
the cellular uptake and endocytosis of dendrimer complexes.  It should be noted that no 
nuclear localization of complexes was observed in this study (Manunta et al., 2004).  
Lauffenburger and coworkers employed biotin-epidermal growth factor (EGF) as the 
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ligand to deliver plasmid DNA encoding the green fluorescent protein to mouse 
fibroblasts bearing the human EGF receptor, and revealed that receptor binding of the 
conjugate, referred to as a rate-limiting step for gene transfer, has been shown to be 
dependent on the ligand cross-linker spacer length used to prepare the conjugate and link 
the targeting molecule onto the polylysine conjugate.  Additionally, the conjugate charge 
ratio and valency determine the receptor-specific delivery process (Schaffer and 
Lauffenburger, 1998).  They further provided evidence that dissociation of the 
polylysine conjugate from the plasmid DNA within the nucleus, as detected via 
fluorescence microscopy and an in vitro transcription assay, has been directly linked to 
structure and polymer length.  These results suggest that vector unpackaging can limit 
the efficiency of gene delivery and expression (Schaffer et al., 2000).  In our work, we 
also demonstrated that TIB-152 Jurkat cells require the dendrimer conjugate of a certain 
size, which has less tendency to aggregate, for optimal gene delivery. 
In conclusion, we were able to determine the kinetic parameters and to provide 
information on the binding and internalization of a number of antibody dendrimer 
conjugates to the IL-2R bearing T cells.  We have shown that the dendrimer conjugate of 
an optimal size, as an endocytosed material, is required for receptor-mediated 
oligonucleotide delivery.  An essential prerequisite for achieving improved 
oligonucleotide delivery is to understand the whole delivery process.  As the delivery 
mechanisms and kinetic parameters are determined experimentally, it will aid 
characterization and design of receptor-mediated antisense delivery vehicles.  This work 
contributes to our ability to provide a detailed fundamental understanding of dendrimer 
conjugate assembly specifically targeting T cells expressing the IL-2R and the associated 
mechanism of oligonucleotide delivery.  This work may aid in our ability to design 
better vehicles for use in delivery of the oligonucleotides for a variety of therapeutic 
applications. 
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CHAPTER VI 
MODELING TARGETED GENE THERAPY 
 
INTRODUCTION 
The ligand-induced internalization of cell surface IL-2/IL-2R complexes occurs 
via an endocytic mechanism (Yu and Malek, 2001).  Mathematical modeling to 
examining receptor-mediated internalization has been widely investigated (Gex-Fabry 
and Delisi, 1984a; Gex-Fabry and Delisi, 1984b; Myers et al., 1987; Chignola et al., 
1994; and others).  Significant work has been done by Lauffenburger and his teams on 
modeling ligand/receptor trafficking systems (Lauffenburger and Linderman, 1993; 
Forsten and Lauffenburger, 1994; Fallon and Lauffenburger, 2000).  Here, we have 
modified existing models to develop a kinetic model of oligonucleotide delivery.  The 
capacity of the delivery vehicle to carry oligonucleotide and affinity of the 
oligonucleotide to the vehicle were considered in our model.  The affinity of the 
antibody to its receptors is a crucial parameter in the delivery of the oligonucleotide to 
the target cells.  The affinity of the antibody-receptor reaction is dependent on both the 
association and dissociation rate constants of the antibody for the receptor, parameters 
considered in this work.  The rate of internalization of conjugates, as a rate limiting 
reaction, plays an important role in our method.  Finally, the degradation of the 
oligonucleotide intracellularly was considered in the model described. 
In the model developed, equivalent parameters that could be obtained from 
experimental data were used to describe the IL-2R targeted therapy.  The model can be 
used to understand better the parameters which govern efficacy and selectivity of a given 
therapy and to aid in the optimization of therapeutic parameters associated with targeted 
gene therapy. 
 
MODEL DEVELOPMENT 
   We propose a one cell model of a T cell that incorporates IL-2R trafficking based 
on models by Lauffenburger and coworkers (Lauffenburger and Linderman, 1993; 
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Forsten and Lauffenburger, 1994; Fallon and Lauffenburger, 2000) and by those of 
Linares (2000).  The model uses mass action kinetics to describe the rate expressions of 
oligonucleotide-antibody dendrimer conjugate binding, binding and internalization of 
oligonucleotide-antibody dendrimer conjugate to the cell receptor, oligonucleotide 
release in the endosome, and degradation of the oligonucleotide. 
   In our model, oligonucleotide (O) is subject to degradation in an extracellular 
environment, Odego (Equation 6.1).  Oligonucleotide binds to an antibody dendrimer 
conjugate (Ab-D) with a capacity, x, to form the oligonucleotide-antibody dendrimer 
conjugate, Ab-D-O.  The oligonucleotide-antibody dendrimer conjugate binds to the IL-
2R at the cell surface (Rs), forming a complex, Ab-D-O-Rs.  The complex is then 
internalized by the receptor.  Once the complex, Ab-D-O-Ri, is localized inside the cell, 
the oligonucleotide is released.  The proposed rate expressions in which a conjugate 
binds to the IL-2R and is internalized by the receptor, followed by the trafficking and 
release of IL-2R (Ri) and oligonucleotide in the endosome (Oi) are given in Equations 
6.2-6.5.  Internalized oligonucleotides may further route to the lysosome, resulting in 
degraded oligonucleotides, Odegi (Equation 6.6). 
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Binding of oligonucleotide to antibody dendrimer conjugate, which corresponds to 
Equation 6.2, can be described by an equilibrium binding reaction.  The equilibrium 
binding affinity constant (K) and binding capacity, x, are defined in chapter IV. 
The corresponding rates of Equations 6.1-6.6 are described by Equations 6.7-
6.13 (see definitions in Table 6.1). 
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Table 6.1.  Definitions and typical units of variables and parameters. 
Symbol                                      Definition                                             Units                      
O                   Oligonucleotide concentration                                           M 
Ab-D             Antibody dendrimer conjugate concentration                    M                           
Ab-D-O        Oligonucleotide-antibody dendrimer conjugate  
                      concentration                                                                      M                           
Rs                  Number of cell surface receptors                                        #/cell 
Cs                  Number of complexes at the cell surface                           #/cell 
NA                 Avogadro’s number                                                            #/mole 
Vc                  Cell volume                                                                        L/cell 
NRsyn             Rate of new receptor synthesis                                           #/cell min-1 
Ci                  Number of internalized complexes                                     #/cell 
Oi                  Oligonucleotide concentration in the endosome                M 
Ri                  Number of free receptors in the endosome                         #/cell 
Ei                   Protein concentration inside the cell                                  mg/mL 
Odego             Degraded oligonucleotide concentration                            M 
Odegi              Degraded oligonucleotide concentration inside the cell     M 
x                    Amount of oligonucleotide per dendrimer                         - 
t                     Localization time                                                               min 
kao                 Association rate constant                                                    M-1 min-1               
kdo                 Dissociation rate constant                                                  min-1 
K                   Equilibrium binding affinity constant                                M-1 
kdego               Degradation rate constant                                                  min-1 
kf                   Forward rate constant                                                         M-1 min-1               
kr                   Reverse rate constant                                                         min-1 
ki                   Internalization rate constant                                               min-1 
kai                  Association rate constant inside the cell                            M-1 min-1                
kdi                  Dissociation rate constant inside the cell                           min-1 
kdegi               Degradation rate constant inside the cell                           (mg/mL)-1 min-1 
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The parameters and estimates for the IL-2R model are listed in Table 6.2.  A simulation 
using the model was performed using Polymath special educational version 5.1 software 
to find the amount of oligonucleotides in the endosome as a function of time.  Results of 
the simulation are shown in Figures 6.1 and 6.2. 
In comparison of simulation results for oligonucleotide internalized for the 
different dendrimers, total predicted oligonucleotide inside the cell without intracellular 
degradation correlates with binding of oligonucleotide to dendrimer conjugate.  We had 
shown in earlier chapters that the binding capacity of the oligonucleotide for dendrimer 
was much less of generation 2.0 than generation 3.0 or 4.0.  As seen in Figure 6.2C, 
oligonucleotide delivery is more effective when the generation 4.0 dendrimer was used. 
In examination of the effect of intracellular degradation of oligonucleotides, it is 
apparent that the effect of degradation is dramatic with all dendrimers tested.  Based on 
simulation results, the rate of intracellular degradation of oligonucleotides plays an 
important role in our method.  These data point to the importance of the delivery vehicle 
protecting oligonucleotide stability intracellularly. 
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Table 6.2.  Parameters and estimates for the IL-2 receptor model. 
Parameter Value Units Reference 
O 
Ab-D 
Rs 
 
 
 
NRsyn 
NA 
Vc* 
Ei* 
xG2.0 
xG3.0 
xG4.0 
kao 
KG2.0 
KG3.0 
KG4.0 
kdego (conditioned) 
kf 
kr 
kiG2.0 
kiG3.0 
kiG4.0 
kdiG2.0 
kdiG3.0 
kdiG4.0 
kdegi (cell lysate) 
3.0·10-5 
1.0·10-8 
690 
 
 
 
29 ± 2 
6.02·1023 
5.2·10-13 
10.9 
0.009 ± 0.002 
0.46 ± 0.02 
1.24 ± 0.05 
1.0·1010 
2.1 ± 0.8·107 
1.2 ± 0.1·107 
8.4 ± 0.9·106 
0.000031 
1.8·109 
0.013 
0.00083 
0.00067 
0.00033 
476 
833 
1190 
0.0121 ± 0.0011 
or 0.0002 
M 
M 
#/cell 
 
 
 
#/cell min-1 
#/mole 
L/cell 
mg/mL 
- 
- 
- 
M-1 min-1 
M-1 
M-1 
M-1 
min-1 
M-1 min-1 
min-1 
min-1 
min-1 
min-1 
min-1 
min-1 
min-1 
(mg/mL)-1 hr-1 
(mg/mL)-1 min-1 
 
 
Personal 
communication with 
Pacheco JR 
 
Linares, 2000 
 
Chapter III 
Chapter III 
Chapter IV 
Chapter IV 
Chapter IV 
 
Chapter IV 
Chapter IV 
Chapter IV 
Chapter III 
Linares, 2000 
Linares, 2000 
Chapter V 
Chapter V 
Chapter V 
 
 
 
Chapter III 
* is based on the cell with an approximate size of 10 µm. 
96 
  
A 
0
1000
2000
3000
4000
0 12 24 36 48 60
Time (hours)
C
om
pl
ex
 a
t C
el
l S
ur
fa
ce
 (#
/c
el
l)
 
B 
0
0.001
0.002
0.003
0.004
0 12 24 36 48 60
Time (hours)
In
te
rn
al
iz
ed
 C
om
pl
ex
 (#
/c
el
l)
 
Figure 6.1.  Model simulation of oligonucleotide delivery using generation 3.0 
dendrimer as the delivery vehicle.  The simulation using the model was performed in the 
presence of intracellular degradation.  (A) Complex at the cell surface is plotted as 
number per cell versus time.  (B) Internalized complex is plotted as number per cell 
versus time.  (C) Internalized oligonucleotide is plotted as number per cell versus time. 
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Figure 6.1.  (Continued) 
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Figure 6.2.  Model simulation of role of intracellular degradation.  The simulation using 
the model was performed in the presence (___) and absence (---) of intracellular 
degradation.  Internalized oligonucleotide is plotted as number per cell versus time.   
(A) Generation 2.0.  (B) Generation 3.0.  (C) Generation 4.0. 
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Figure 6.2.  (Continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 
  
CHAPTER VII 
CONCLUSIONS AND RECOMMENDATIONS 
 
The effectiveness of most chemotherapeutic regimens is limited by the toxicity of 
the therapy to normal healthy cells.  Therapies to selectively modulate abnormal T cells 
bearing the IL-2R have been developed to treat diseases associated with immune 
disorders.  The goal of the research described in this work was to develop the 
engineering or rational design of agents which deliver oligonucleotides to specific T 
cells to selectively and effectively modulate immune response; and to examine the steps 
and key components in the mechanism underlying oligonucleotide delivery. 
 
CONCLUSIONS 
The expression of the IL-2R α chain on some abnormal cells provides us with a 
target and the opportunity to selectively destroy these cells.  Such strategies have been 
the focus of therapeutic intervention associated with lymphoid malignancies, select 
autoimmune diseases, GVHD, and allograft rejection.  Oligonucleotide therapeutic 
approaches are designed to introduce genetic materials into abnormal cells to modulate 
the expression of a target protein.  Steps involved in oligonucleotide transfer include 
cellular uptake, intracellular trafficking, and (if necessary) nuclear translocation.  The 
aim of this body of research was, taking advantages of engineering approaches, (1) to 
investigate the specificity and efficacy of oligonucleotide delivery using a monoclonal 
antibody for targeting and a positively charged PAMAM dendrimer as the carrier for the 
oligonucleotide to the IL-2R bearing T cells; (2) to examine the relative stability of 
oligonucleotides in a cellular environment; and (3) to explore the properties including 
toxicity of the dendrimer delivery vehicle, the binding capacity of the vehicle, affinity of 
the vehicle for oligonucleotides, and cellular uptake of the vehicle for oligonucleotide 
delivery. 
First, we examined the effect of oligonucleotides with different backbone 
chemistries on cell viability in the presence and absence of dendrimer delivery vehicle.  
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In all cases, the oligonucleotides had relatively low toxicity in the model leukemia cell 
line used in our experiments. 
We describe the development of an HPLC method to examine the relative 
stability of oligonucleotides against intracellular and extracellular nucleases.  Using a 
size exclusion HPLC technique, we were able to determine the portions of the 
oligonucleotide based on the difference in size and/or molecular mass that were 
degraded during incubation.  Data from the degradation assay and parameter estimation 
suggest that the rate of intracellular degradation was much greater than extracellular 
degradation.  
To further protect oligonucleotides from intracellular degradation, the 
oligonucleotide was complexed to the dendrimer.  We developed a cationic-exchange 
HPLC method using a linear salt gradient to separate the oligonucleotide and the 
dendrimer.  Our results showed that almost 100% of the oligonucleotide was separated 
from the dendrimer complex.  It should be noted that considerable aggregation of 
discrete particles was observed while incubating the complexes in cell lysate.  We 
further examined this aggregation phenomenon.  Several attempts had been made in 
order to dissolve the pellets.  However, we were unable to dissolve these resulting 
aggregates, suggesting that the complexes and cell lysate may have an inherent tendency 
toward aggregation under physiological buffer conditions. 
An investigation of the properties of the dendrimer vehicles, toxicity, binding 
capacity and binding affinity, as a function of dendrimer generation, was carried out.  
We conducted an equilibrium binding analysis as well as estimation of equilibrium 
binding constant of oligonucleotides to dendrimers.  The binding capacity of the same 
dendrimer was also examined as a function of the ionic strength of the buffers.  Our 
results address the importance of the complex formation between the delivered 
oligonucleotide and a carrier, which may aid in the design of a more effective 
therapeutic vehicle for oligonucleotide delivery. 
The kinetic and thermodynamic analysis of a delivery vehicle of an antibody 
dendrimer conjugate was performed as a function of dendrimer generation.  Vehicle 
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delivery involves binding of the vehicle to the receptor and internalization of the 
receptor-vehicle complex.  According to our results, the dendrimer conjugate of a certain 
size and surface charge, which has less tendency to aggregate, is required for receptor-
mediated oligonucleotide delivery.  More importantly, the internalization plays a pivotal 
role as a rate limiting step in the mechanism of oligonucleotide delivery.  
Finally, a mathematical model was developed to study the IL-2R targeted gene 
therapy.  In vitro data are incorporated into derived rate equations to predict the 
performance.  This part of the work demonstrates the utility of an engineering approach 
to examining therapeutic parameters based on the targeting of the IL-2R, and could 
provide insight into the design and optimization of immunomodulatory therapy. 
In summary, this body of research explores the engineering or rational design of 
targeted oligonucleotide delivery vehicles selectively to T cells expressing the IL-2R.  
The ability to predict the effects of different delivery vehicle properties on 
oligonucleotide delivery may aid in the development of design criteria for new vehicles 
for delivery of antisense, siRNA, or genes to IL-2R bearing cells. 
 
RECOMMENDATIONS  
Validation of the Biological Effect of PDE1B1 mRNA   
Our results showed that the oligonucleotides fail to significantly affect cell 
viability.  To better measure its biological effect, studies would need to examine if the 
oligonucleotide is able to lead to reduced levels of cellular mRNA of the gene of 
interest, and to lead to attenuated protein levels, independent of cell survival.  The results 
from western blotting along with DNA fragmentation analysis might give complete 
information on the biological response to oligonucleotide.  We believe these results 
would enable us to better explain our previous data. 
 
Identification of Genes in Jurkat Cells  
Our results showed that the oligonucleotides had relatively low toxicity effect.  
To select more effective sequences, it would be useful to obtain more details of relevant 
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gene targets.  The polymerase chain reaction along with direct DNA sequencing might 
be useful for amplifying genes encoding proteins in Jurkat leukemia T cells. 
 
Interaction between the Dendrimer Complex and Cell Lysate   
We were unable to characterize to our satisfaction the effect of dendrimer on rate 
of degradation of oligonucleotide intracellularly, in part because the dendrimer-
oligonucleotide complex aggregated in cell lysate.  In examining the effect on the 
aggregation of the dendrimer complexes in cell lysate, several suitable non-charged 
detergents need to be found and used to dissolve the pellets.  In addition, an antibody 
dendrimer conjugate with altered affinity might be used in experiments to examine the 
effect of the complex in oligonucleotide degradation experiments. 
 
Optimization of IL-2 Receptor Targeted Gene Delivery Vehicle  
Optimization of the delivery vehicle has proven to be critical to enhance the rate 
of internalization of oligonucleotide.  Some evidence revealed that the fractured 
dendrimer increased transfection efficiency due to its increased degree of flexibility.  In 
the future, we might explore the effect of fractured dendrimers in internalization, 
binding, and stability experiments to further optimize our delivery vehicle. 
 
Specificity of Oligonucleotide Delivery   
The original goal of this work was to demonstrate that we could specifically and 
effectively deliver an oligonucleotide to cells which would affect cell cycle and result in 
reduction in proliferation or death of a specific population of cancerous T cells.  While 
we were able to deliver oligonucleotide to T cells, we were never able to effectively kill 
those cells with the antisense and small interfering RNA’s chosen.  Therefore, we never 
tested the specificity of the therapy.  Once an appropriate oligonucleotide is found that 
will actually reduce proliferation of cells, it would be useful then to test the vehicle and 
oligonucleotide against irrelevant cell lines. 
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APPENDIX 
 
MEASUREMENT OF OLIGONUCLEOTIDE BINDING TO DENDRIMERS 
Conjugation of Dendrimers to Gels 
 The H2N-terminated and HOOC-terminated dendrimers were coupled to 
aminolink and immobilized DADPA gels, respectively, according to the manufacturer’s 
instruction.  Table A.1 summarizes the conjugation efficiency for coupling of 
dendrimers to gels. 
 
Estimation of Nonspecific Binding of Oligonucleotides to Quenched Gels 
 The total binding can be expressed as the simple sum of specific and nonspecific 
binding (Equation A.1).  
 [ ] [ ] [ ]T S NSB B B= +        (A.1) 
For an aminolink gel, the nonspecific binding of oligonucleotide to the gel was 
negligible, while for an immobilized DADPA gel, isotherms were corrected for 
nonspecific binding.  If we can assume that the nonspecific binding is a linear function 
of the oligonucleotide concentration, then the observed binding will be described as: 
 [ ] [ ] [ ]T S gelB B aV F= +        (A.2)  
where a is a constant and Vgel represents the volume of quenched gel.  A linear least 
squares regression analysis of binding of oligonucleotides to the quenched DADPA gel 
(Figure A.1) is given a constant of 0.0953 µL-1. 
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Table A.1.  Summary of conjugation efficiency for coupling of dendrimers to gels. 
 
Generation                                                               %Conjugation efficiency   
2.0                                                                              47.7 
3.0                                                                              52.1 
3.5*                                                                            39.8 
4.0                                                                              75.9 
4.5                                                                              34.5 
* indicates 2-fold mole loading of dendrimer in the coupling reaction compared with 
other dendrimers. 
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Figure A.1.  Nonspecific binding of FITC-labeled oligonucleotides to quenched 
DADPA gel.  Experiments were conducted at room temperature in phosphate buffer 
saline (PBS, 13.67 mM NaCl, 2.68 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2 PO4)  
at pH 7.2.  The amount of oligonucleotide bound to the quenched gel is plotted versus 
concentration of free oligonucleotide. 
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